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A B S T R A C T
Background
Urinary schistosomiasis is caused by an intravascular infection with parasitic Schistosoma haematobiumworms. The adult worms typically
migrate to the venous plexus of the human bladder and excrete eggs which the infected person passes in their urine. Chronic infection
can cause substantial morbidity and long-term complications as the eggs become trapped in human tissues causing inflammation and
fibrosis. We summarised evidence of drugs active against the infection. This is new edition of a review first published in 1997.
Objectives
To evaluate the efficacy and safety of drugs for treating urinary schistosomiasis.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register, MEDLINE, CENTRAL, EMBASE and LILACS and
reference lists of articles up to 23 May 2014.
Selection criteria
Randomized controlled trials (RCTs) of antischistosomal drugs and drug combinations compared to placebo, no intervention, or each
other.
Data collection and analysis
Two researchers independently screened the records, extracted the data and assessed risk of bias. The primary efficacy outcomes were
parasitological failure (defined as the continued presence of S. haematobium eggs in the urine at time points greater than one month
after treatment), and percent reduction of egg counts from baseline.We presented dichotomous data as risk ratios (RR), and continuous
data as mean difference (MD), alongside their 95% confidence intervals (CIs). Where appropriate we combined trials in meta analyses
or tables. We assessed the quality of evidence using the GRADE approach.
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Main results
We included 30 RCTs enrolling 8165 participants in this review. Twenty-four trials were conducted in children in sub-Saharan Africa,
and 21 trials were over 20 years old. Many studies were assessed as being at unclear risk of bias due to inadequate descriptions of study
methods.
Praziquantel
On average, a single 40 mg/kg dose of praziquantel reduced the proportion of people still excreting eggs in their urine by around
60% compared to placebo at one to two months after treatment (treatment failure: RR 0.42, 95% CI 0.29 to 0.59, 864 participants,
seven trials, high quality evidence). The proportion of people cured with praziquantel varied substantially between trials, from 22.5%
to 83.3%, but was higher than 60% in five of the seven trials. At one to two months following praziquantel treatment at 40 mg/kg,
the mean number of schistosome eggs in the urine was reduced by over 95% in five out of six trials (678 participants, six trials, high
quality evidence).
Splitting praziquantel 40 mg/kg into two doses over 12 hours probably has no benefits over a single dose, and in a single trial of 220
participants the split dose caused more vomiting (RR 0.5, 95% CI 0.29 to 0.86) and dizziness (RR 0.39, 95% CI 0.16 to 0.94).
Metrifonate
A single dose of metrifonate 10 mg/kg reduced egg excretion (210 participants, one trial, at eight months), but was only marginally
better than placebo at achieving cure at one month (RR 0.83, 95% CI 0.74 to 0.94, 142 participants, one trial). In a single trial
comparing one, two and three doses, the absolute number of participants cured improved from 47% after one dose to 81% after three
doses (93 participants, one trial, low quality evidence).
Two small trials compared 40 mg/kg single dose praziquantel with two or three doses of 10 mg/kg metrifonate and found no clear
evidence of differences in cure (metrifonate 2 x 10 mg/kg at one month: RR 1.03, 95% CI 0.8 to 1.34, 72 participants, one trial;
metrifonate 3 x 10 mg/kg at three months: RR 0.33, 95% CI 0.07 to 1.57, 100 participants, one trial. In one trial both drugs performed
badly and in one trial both performed well.
Other drugs
Three trials have evaluated the antimalarial artesunate; with inconsistent results. Substantial antischistosomal effects were only seen in
one of the three trials, which was at unclear risk of bias due to poor reporting of the trial methods. Similarly, another anti-malarial
mefloquine has been evaluated in two small trials with inconsistent effects.
Adverse events were described as mild for all evaluated drugs, but adverse event monitoring and reporting was generally of low quality.
Authors’ conclusions
Praziquantel 40 mg/kg is the most studied drug for treating urinary schistosomiasis, and has the strongest evidence base.
Potential strategies to improve future treatments for schistosomiasis include the combination of praziquantel with metrifonate, or
with antimalarial drugs with antischistosomal properties such as artesunate and mefloquine. Evaluation of these combinations requires
rigorous, adequately powered trials using standardized outcome measures.
P L A I N L A N G U A G E S U M M A R Y
Drugs for treating urinary schistosomiasis
What is urinary schistosomiasis and how is it treated?
Urinary schistosomiasis is a disease caused by infection of people with the parasitic worm Schistosoma haematobium. These worms live
in blood vessels around the infected person’s bladder and the worm releases eggs which are released in the person’s urine. If the urine
is passed into ponds or lakes, the eggs can hatch and infect people that are washing or swimming there. Infection can cause blood in
the urine and if left untreated can eventually lead to anaemia, malnutrition, kidney failure, or bladder cancer. Urinary schistosomiasis
is diagnosed by looking for worm eggs in the urine.
The disease occurs mainly in school-aged children and young adults in sub-Saharan Africa. The drug currently recommended for
treatment is praziquantel, which can be given as a single dose, but other drugs such as metrifonate, artesunate, and mefloquine have
also been evaluated.
2Drugs for treating urinary schistosomiasis (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
After examining the research published up to 23th May 2014, we included 30 randomized controlled trials, enrolling 8165 children
and adults.
What does the research say?
On average, the standard dose of praziquantel cures around 60% of people at one to two months after treatment (high quality evidence),
and reduces the number of schistosome eggs in the urine by over 95% (high quality evidence).
Metrifonate, an older drug no longer in use, had little effect when given as a single dose but an improved effect when given as multiple
doses two weeks apart. Two trials compared three doses of metrifonate with the single dose of praziquantel and found similar effects.
Two more recent trials evaluated a combination of artesunate and praziquantel compared to praziquantel alone. In one trial artesunate
improved cure and in one it made no difference.
Authors conclusions
Future treatments for schistosomiasis could include combining praziquantel with metrifonate, or with artesunate, but these need to be
evaluated in high quality trials.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Praziquantel 40 mg/kg versus placebo for treating urinary schistosomiasis
Patient or population: People with urinary schistosomiasis
Settings: Endemic areas in sub-Saharan Africa
Intervention: Praziquantel 40 mg/kg (single dose) versus placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Placebo Praziquantel 40 mg/kg
Parasitological failure
At 1 to 2 months
91 per 100 38 per 100
(26 to 54)
RR 0.42
(0.29 to 0.59)
864
(7 trials)
⊕⊕⊕⊕
high1,2,3,4
Percentage egg reduction
At 1 to 2 months
Mean change in egg excretion
in the control groups ranged
from a 53.2% reduction to a
138% increase.
Mean egg excretion in the
intervention groups was re-
duced by>98% in all trials
Not pooled 678
(6 trials)
⊕⊕⊕⊕
high1,2,3,5
Microhaematuria
At 8 weeks
53 per 100 28 per 100
(17 to 45)
RR 0.53
(0.33 to 0.84)
119
(1 trial)
⊕⊕©©
low6,7,8
Haemoglobin
At 6 to 8 months
The mean haemoglobin
ranged across control groups
from
11.3 to 11.9 G/dL
The mean haemoglobin in the
intervention groups was 0.08
G/dL lower
(0.24 lower to 0.09 higher)
- 727
(2 trials)
⊕⊕⊕©
moderate3,9,1011
Adverse events - - - 1591
(9 trials)
⊕⊕©©
low12
The basis for the assumed risk is the mean risk in the control groups across trials. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 No serious risk of bias: Several trials were at unclear or low risk of selection bias. However, a sensitivity analysis excluding these trials
still found a strong effect.
2 No serious inconsistency: Six of the seven trials found large consistent effects. The seventh trial found no difference, this may be
explained by the different diagnostic criteria used in this trial.
3 No serious indirectness: These seven trials are all conducted in children in endemic areas of sub-Saharan Africa.
4 No serious imprecision: The result is statistically significant and the 95% CI is narrow around a clinically important effect.
5 No serious imprecision: The trials are small and most did not report tests of statistical significance, however the differences are large.
6 No serious risk of bias: This trial was well conducted.
7 Downgraded by 1 for serious indirectness: Only a single trial reports this outcome. Further trials from different settings would be needed
to be confident in this effect.
8 Downgraded by 1 for serious imprecision: This trial is underpowered.
9 Downgraded by 1 for serious risk of bias: both trials had inadequate sequence generation and allocation concealment.
10 No serious inconsistency: Low statistical heterogeneity.
11 No serious imprecision: only two trials reported this outcome. CIs are narrow. The effect is not statistically significant and does not
appear to be clinically important, when compared to the baseline data.
12 Downgraded by 2 for serious risk of bias: Three trials do not comment on adverse events. Six trials made comments that praziquantel
was generally well tolerated and no statistically significant differences were noted. However, adverse events were poorly reported in all
six trials such that meta-analysis, and assessment of other quality criteria was not possible.
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B A C K G R O U N D
Urinary schistosomiasis, also called bilharzia or snail fever, is an in-
travascular infection caused by parasitic Schistosoma haematobium
worms. It is endemic in sub-Saharan Africa, the Arabian peninsula
and the Middle East. According to the World Health Organiza-
tion (WHO), at least 243 million people required treatment for
schistosomiasis in 2011 (WHO2013), andmore than 700 million
people live in endemic areas (WHO 2014).
TheWHO currently recommends regular chemoprophylaxis with
praziquantel for populations at risk to prevent the long term con-
sequences of infection. These programmes usually target school
children (Table 1), but may be extended to the whole community
in high risk settings (King 2011).
Description of the condition
Human infectionwith S. haematobium is acquired through contact
with water bodies containing cercariae, the larval form of the par-
asite. The cercariae are able to penetrate human skin and migrate
via blood vessels to the liver, where they mature into male and fe-
male forms for reproduction. Typically, they then migrate further
to the venous plexus of the urinary bladder, and begin to produce
eggs which the infected person excretes in their urine (Gryseels
2006). If these eggs reach water, they hatch into miracidia, infect
specific freshwater snails which act as intermediate hosts, before
emerging as cercariae that can infect humans (Gray 2011; Ross
2002).
Any illness associated with acute infection is typically mild, but
chronic schistosomiasis can cause considerable morbidity with
chronic pain, anaemia, fatigue, under nutrition and reduced exer-
cise tolerance (King 2005). A review of 124 observational studies
and 11 randomized controlled trials (RCTs) in 2005 estimated
that up to 15% of people infected with any form of schisto-
somiasis suffer disabling long-term complications (King 2005).
The main pathological process occurs when schistosome eggs be-
come trapped in the tissue around the bladder and ureters causing
chronic inflammation, which may obstruct the ureters, damage
the kidneys, and lead to bladder cancer. Occasionally, eggs can
become trapped in other tissues such as the brain and spinal cord
(WHO 1985).
Two-thirds of all infected persons are schoolchildren (aged five to
14 years), and the intensity of infection with S. haematobium is
highest in children aged ten to 14 years (WHO 1985).
The standard test for urinary schistosomiasis is urine filtration
and microscopic examination of the urine sample (WHO 1991).
The urine sample is passed through a filter paper and the eggs
retained on the filter are counted either with or without staining.
Sedimentation and centrifugation is less commonly used for urine
concentration (Cook 2003). High urine egg counts are related to
high infection intensity.
Parasitologists define cure when eggs can no longer be detected
in one or more urine samples using standard methods. Besides
parasitological cure, researchers also record the relative reduction
in egg output after treatment compared to pre-treatment levels.
This outcome, expressed as% egg reduction, is an indirect estimate
of a reduction of the worm burden (Cook 2003).
Blood and protein excretion in the urine is usually elevated in
urinary schistosomiasis and decreases when the infection resolves.
The most commonly used test is a dipstick test. Ultrasound can
demonstrate organ involvement of the urinary tract as well as its
resolution.
Description of the intervention
Praziquantel is the current treatment for urinary schistosomia-
sis recommended by the WHO (WHO 2006). Historically, met-
rifonate was also used but this fell out of favour due to the
need for multiple doses (Feldmeier 1999; WHO 1998). More re-
cently, there has been interest in the antischistosomal properties of
artemisinin derivates and mefloquine, more commonly used for
treating malaria (Utzinger 2004).
Praziquantel is an pyrazinoisoquinoline derivative with activity
against adult worms of all schistosome species (S. mansoni, S. in-
tercalatum and S. japonicum), but not against maturing worms.
Praziquantel has a rapid onset of action. It is well-tolerated, can be
given as a single dose (Utzinger 2004) and paediatric formulations
are available (Stothard 2013).
Metrifonate, an organophosphorous cholinesterase inhibitor, is
active against S. haematobium but not against other schistosome
species (Utzinger 2004).
Artemisinin, extensively used as potent antimalarial, has highest
activity against immature schistosomes. Artemsinins are safe and
well-tolerated (Utzinger 2004).
How the intervention might work
After treatmentwith praziquantel, the worms appear to die quickly
but egg excretion continues for several weeks. There are several
possible reasons for this:
• Firstly, some worms might not have been mature at the
time of praziquantel treatment and therefore not killed by
praziquantel (Cioli 2003). Maturation of the worms after
infection takes four to six weeks, and after two months eggs can
be detected in the urine.
• Secondly, the patient might have been re-infected (Cioli
2003).
• Thirdly, dead eggs still wander out of the tissue into the
urine several weeks after clearing adult worms (Taylor 1988
ZWE). Therefore, a follow-up four to six weeks after treatment is
useful (Renganathan 1998). There is also considerable variation
in daily urinary egg output (Cook 2003).
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Although there is concern that S. haematobium might develop re-
sistance against praziquantel (Fenwick 2006), there is no clinically
relevant evidence for resistance up to now (Doenhoff 2008).
In endemic settings, reinfection with S. haematobium is likely, and
cure (often defined as complete cessation of egg excretion) is not
a sustainable long term goal. However, reduction of infection in-
tensity results in clinical improvement, low morbidity and pre-
vention of long term complications. Therefore, WHO promotes
morbidity control rather than cure as an objective for schistoso-
miasis control programmes (WHO 2002).
Why it is important to do this review
At present, praziquantel as the only drug in use that is exposed
to resistance development. It is therefore important to monitor its
performance and to assess the effects of other drugs against urinary
schistosomiasis.
Dosing regimens for subgroups such as highly infected patient
groups, incremental benefits of drug combinations, double dos-
ing and optimal interval between doses have to be determined to
inform control programmes for urinary schistosomiasis.
Paediatric schistosomiasis has gained attention as a public health
problem, and evaluation of existing treatment studies is indicated.
O B J E C T I V E S
To evaluate the efficacy and safety of drugs for treating urinary
schistosomiasis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials.
Types of participants
Patients diagnosed with urinary schistosomiasis by:
• detection of macro or microhaematuria;
• identification of schistosome eggs by urine microscopy;
• detection of parasite antigens in blood or urine.
Types of interventions
Intervention
Drugs used to treat urinary schistosomiasis. Drugs considered
as obsolete (such as ambilhar, oltipraz and niridazole) were not
included. Metrifonate was included.
Control
Placebo, no intervention, an alternative regimen of the same drug,
or an alternative drug used to treat urinary schistosomiasis.
Types of outcome measures
Primary outcomes
• Parasitological failure at one month post-treatment (as
defined by the trial authors);
• Percent egg reduction at one month.
Secondary outcomes
• Parasitological failure at time-points > one month;
• Percent egg reduction from baseline at > one month;
• Clinical outcomes: resolutions of signs and symptoms (for
example, haematuria and proteinuria);
• Anaemia (decrease of the number of red blood cells or the
quantity of haemoglobin in the blood);
• Growth outcomes (gain in body weight, body length).
Adverse events
• Serious adverse events;
• Other adverse events
Search methods for identification of studies
We attempted to identify all relevant trials regardless of language
and publication status (published, unpublished, in press, under
review and in progress).
Electronic searches
We searched the following databases using the search terms out-
lined in Appendix 1: The Cochrane Infectious Diseases Group
Specialized Register (23 May 2014); Cochrane Central Register of
ControlledTrials (CENTRAL), published inTheCochrane Library
(2014, Issue 4); MEDLINE (1966 to 23 May 2014); EMBASE
(1974 to 23May 2014); and LILACS (1982 to 23May 2014). We
also searched themetaRegister of Controlled Trials (mRCT) using
’Schistosoma haematobium’ as the search term (23 May 2014).
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Searching other resources
We checked the reference lists of all studies identified by the above
methods for additional studies relevant to this review.
Data collection and analysis
Selection of studies
Vittoria Lutje, the Cochrane Infectious Diseases Group (CIDG)
Information Retrieval Specialist, searched the literature and re-
trieved trial titles and abstracts.
VK and FZ independently screened the results of the search and
retrieved full trial reports of all potentially relevant trials. Then,
VK and FZ independently assessed each trial for inclusion using
an eligibility form based on the inclusion criteria. We resolved any
discrepancies by discussion with PG.
Data extraction and management
VK and FZ independently extracted data using pre-tested stan-
dardized forms. We resolved any differences through discussion
with PG. For each trial we extracted details of the trial methods,
participants, interventions and outcomes.
VK and FZ extracted the number of participants randomized and
number of participants followed up in each treatment arm. For
dichotomous outcomes, we extracted the number of participants
experiencing the event in each group. For continuous outcomes
summarized as geometric means, we extracted means and their
standard error, if reported. If the data were presented as arithmetic
means, we extracted arithmetic means and their standard devia-
tions (SD), if reported, for each treatment group. Where contin-
uous data were summarized as medians and ranges, these were ex-
tracted and entered into tables.
VK and FZ double-entered the data and cross-checked to min-
imise errors. VK tried to contact trial authors for clarification or
insufficient of missing data when necessary and summarised data
reported in multiple publications as one single data set.
Assessment of risk of bias in included studies
VK and FZ independently assessed the risk of bias of each trial
using an assessment form based on the Cochrane Collaboration’s
’Risk of bias’ tool (Higgins 2008). DS verified the assessment re-
sults.
We assessed the risk of bias for six domains: sequence generation;
allocation concealment; blinding (of participants, personnel, and
outcome assessors); incomplete outcome data; selective outcome
reporting; and other sources of bias. We categorized these judg-
ments as low, high or unclear risk of bias.
For sequence generation, allocation concealment and blinding, we
quoted the method as described in the trial in the Characteristics
of included studies tables. For blinding, we stated the blinding
method and who was blinded separately for different outcomes.
For incomplete outcome data, we assigned a judgement for dif-
ferent outcomes (for example, loss to follow-up at different time
points).
We resolved disagreements by discussion or consultation. Where
risk of bias was unclear, we attempted to contact the trial authors
for clarification.
Measures of treatment effect
We presented dichotomous outcomes as risk ratios (RR), and con-
tinuous outcomes as mean differences or geometric mean ratios.
All results are shown with a 95% confidence interval (CI).
Unit of analysis issues
For trials includingmore than two comparison groups, we split and
analysed as individual pair-wise comparisons. When conducting
meta-analysis we ensured that participants and cases in the placebo
group were not counted more than once, by dividing the placebo
cases and participants evenly between the intervention groups.
Dealing with missing data
The primary analysis is a complete case analysis where the number
of evaluable participants at each time point is used as the denom-
inator.
Assessment of heterogeneity
We assessed heterogeneity by inspecting forest plots for overlap-
ping CIs and outlying data.We applied theChi2 test with a P value
< 0.10 to indicate statistically significant heterogeneity, and the I
2 statistic with a value of greater than 50% to indicate moderate
heterogeneity.
Assessment of reporting biases
We planned to evaluate the possibility of publication bias by con-
structing funnel plots, but there were too few trials within each
comparison to make this meaningful.
Data synthesis
We analysed the data in pair-wise comparisons using Review
Manager (RevMan). We stratified the primary analysis by drug
dose and the time point after treatment. Data were combined in
meta-analyses using a fixed-effect model. If we detected moderate
heterogeneity but still considered combination of the trials to be
appropriate we used a random-effects model. We presented data
which could not be presented in forest plots in tables (medians,
means without measure of variance, ranges).
We assessed quality of evidence using the GRADE approach, and
displayed the results in ’Summary of Findings’ tables. TheGRADE
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approach defines quality as a measure of ’our confidence in the
effect estimates’ and defines four levels of quality; high, moderate,
low and very low. The evidence fromRCTs is rated as ’high quality’
but can be downgraded where there are major concerns about:
1) the risk of bias of the trials; 2) inconsistency between the trial
results; 3) a mismatch between the question being asked and the
trial setting, population, intervention or control; 4) the trial being
underpowered; or 5) evidence of publication bias.
Subgroup analysis and investigation of heterogeneity
Weplanned to conduct the following subgroup analyses to explore
the potential causes of heterogeneity. However, there were too few
trials within each comparison to make this meaningful: patient
age (children versus adults), intensity of infection, endemicity.
Sensitivity analysis
Data were insufficient to assess the robustness of results by sensi-
tivity analyses to evaluate risk of bias components and the effects
of missing data.
R E S U L T S
Description of studies
Results of the search
Following database searches, we identified 116 individual cita-
tions, and a further 40 potential studies after we checked trial ab-
stracts. Following abstract screening, we assessed 71 full text arti-
cles for inclusion. Figure 1 shows the flow diagram of these trials.
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Figure 1. Study flow diagram
10Drugs for treating urinary schistosomiasis (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Included studies
We included 30 RCTs, enrolling 8965 participants, and reported
in 39 publications. Twenty trials were over 20 years old, and only
eight were published since the year 2000.
Settings
All but one trial were conducted in sub Saharan Africa; 13 trials
from East Africa: Somalia (one) Sudan (three), Tanzania (two),
Kenya (six), Malawi (one); 13 trials from West Africa: Cameroon
(two), Gabon (three), Niger (two),Mali (one),Nigeria (two), Cote
d’ Ivoire (one), Ghana (one), Gambia (one); and three trials from
southern Africa: Zimbabwe (two), and Zambia (one). Most trials
were based in rural settings, but two were conducted in peri-ur-
ban or semi-rural settings, three were from urban settings, and in
one trial the setting was not described. The remaining trial was
conducted in an urban setting in Saudi Arabia.
Twenty trials were based in schools and one in a college, seven in
villages, farms or settlements, one in antenatal clinics and two in
referral hospitals.
Participants
Twenty-four trials enrolled school-age children and young adults,
although the exact age-range varied; age six to 20 years (16 trials),
age five to 18 years (three trials), age two to 23 years (five trials).
Two trials enrolled adults only, and four trials didn’t clearly state
the age range.
All trials diagnosed S. haematobium infection by detection of
eggs or miracidia on urine microscopy. Sixteen trials reported egg
counts as geometric mean egg counts, four trials as arithmetic
mean egg counts, three trials reported both. One study reported
geometric mean miracidial counts. Six trials used ranges or medi-
ans.
Interventions
Eight trials compared praziquantel with placebo, and 14 trials
published between 1981 and 2009 compared different doses or
regimens of praziquantel.
Five trials compared metrifonate with placebo, and seven trials
published between 1983 and 1990 directly compared the efficacy
of praziquantel and metrifonate.
More recently, three trials published between 2001 and 2009 eval-
uated artesunate as single agent or in combination with praziquan-
tel, and two trials published in 2009 and 2011 evaluated meflo-
quine.
Excluded studies
We excluded 65 studies for the reasons given in the ’Characteristics
of excluded studies’ table.
Risk of bias in included studies
Many trials lacked adequate descriptions of methods to allow
judgements on risk of bias, and so have been classified as unclear
(see Figure 2).
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
trial.
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Allocation
Fourteen trials adequately described a randommethod of sequence
generation, but only six described a method of allocation conceal-
ment and could be considered at low risk of selection bias (Abden
Abdi 1989 SOM; Basra 2012 GAB; Borrmann 2001 GAB; Olds
1999 KEN; Pugh 1983 MWI; Sacko 2009 MLI).
Blinding
Ten trials reported adequate attempts to blind participants and
trial staff to treatment allocation, six trials were unblinded and
blinding was unclear in the remaining trials. Seven trials reported
adequate blinding of outcome assessors.
Incomplete outcome data
Many trials had high levels of attrition, particularly at later time
points. When trials presented cure or failure rates as percentages,
we were unable to assess attrition. We considered the risk of attri-
tion bias to be unclear in 13 trials and high in nine trials.
Selective reporting
We found evidence of reporting bias in one trial, as trial authors
did not present pre-specified outcomes. In three trials, selective
reporting was at unclear risk of bias.
Other potential sources of bias
Trial authors reported baseline imbalances in two trials, which we
identified as sources of other bias.
The trials were mostly funded by funds, trusts or international
agencies (see Characteristics of included studies tables). Eight trials
did not declare funding, four received drug donations and only
two trials declared funding by pharmaceutical companies (both
Dafra Pharma).
Effects of interventions
See:Summary offindings for themain comparisonPraziquantel
40 mg/kg versus placebo for treating urinary schistosomiasis;
Summary of findings 2 Praziquantel 40 mg/kg single dose versus
30 mg/kg single dose; Summary of findings 3 Praziquantel 40
mg/kg multiple doses versus single dose; Summary of findings 4
Metrifonate 3 x 7.5 mg/kg given two weeks apart versus placebo;
Summary of findings 5 Artesunate versus placebo; Summary of
findings 6 Praziquantel and artesunate versus praziquantel
Section A: Praziquantel
Praziquantel 40 mg/kg single dose versus placebo
(comparison 1)
On average, a single 40 mg/kg dose of praziquantel reduces the propor-
tion of people still excreting eggs at one to two months after treatment
by around 60% compared to placebo, and reduces the mean number
of eggs excreted by over 95%.
Eight trials compared a single 40 mg/kg dose of praziquantel with
placebo or no treatment in schoolchildren in sub-Saharan Africa.
We have listed the definitions of parasitological failure in Table 2.
Parasitological failure
Praziquantel 40 mg/kg as a single dose reduced parasitological
treatment failure by around 60% at one to two months compared
to placebo (RR 0.42, 95% CI 0.29 to 0.59; 864 participants,
seven trials, Analysis 1.1). The absolute level of treatment failure
with praziquantel ranged from 16.6% (McMahon 1979 TZA) to
77.5% (de Jonge 1990 SDN). Treatment failure with placebo was
greater than 80% in all seven trials and over 90% in four trials.
Four trials reported follow-up beyond two months (Analysis 1.1).
Failure rate increased over time in two trials, as might be expected
in areas of schistosomiasis transmission as people become re-in-
fected (McMahon 1979 TZA; Pugh 1983 MWI). However, treat-
ment outcomes improved in Taylor 1988 ZWE over time, with
moderate reductions in treatment failure at one month and three
months and a 70% reduction at six months. The trial authors
stated that this improvement might have been due to excretion of
remaining eggs from the urinary tract over time.
The fourth trial, de Jonge 1990 SDN, found no difference in
treatment failure between praziquantel and placebo at any time
point. The trial authors used a more sensitive diagnostic method
(three urine samples, filtration of the whole volume up to 350 mL
when the 10 mL urine sample contained fewer than 10 eggs) and
a strict definition of cure (no excretion of eggs, no viability testing
of eggs). This may explain the high failure rates observed despite
high percent egg reductions comparable to other trials.
Stephenson 1989 KENreported treatment failure at eightmonths,
its only time point. A single dose of praziquantel reduced treatment
failure by 86% compared to placebo (RR 0.14, 95% CI 0.08 to
0.22; 209 participants, one trial, Analysis 1.1).
Six trials reported parasitological failure stratified by intensity of
infection; the categorisation of strata varied between trials (642
participants, see Appendix 2). At the first follow-up at four to six
weeks, three out of four trials had a tendency to higher failure in
participants with higher infection intensity. The pattern attenu-
ated at later time points.
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Percent egg reduction
Seven trials reported mean urine egg counts per 10 mL urine at
baseline, and at one to two months after a single dose of prazi-
quantel 40 mg/kg or placebo (867 participants, seven trials, see
Table 3), although we were only able to reliably interpret this data
for six trials (678 participants).
The mean egg count was reduced by more than 95% at one to two
months following praziquantel in five trials, and by 75% in one
trial. In the placebo groups the change in mean egg count ranged
from a 53% decrease to a 115% increase.
Percent egg reduction in the praziquantel group remained high
(> 95%) in all three trials reporting at three months, and in all
four trials at six months. Percent egg reduction was variable in the
placebo group, ranging from 26% increase to 54% reduction at
three months and from 5% to 64% reduction at six months (see
Table 4). One additional trial, Stephenson 1989 KEN, reported
percent egg reduction at eight months as its only time point (209
participants, see Table 4). Percent egg reduction after praziquantel
was 99% compared to 5% with placebo.
Five trials reported percent egg reduction stratified by intensity
of infection (764 participants, Appendix 2). At four to six weeks,
all trials reported percent egg reductions over 90% across the
strata. Percent egg reduction as a relative measure was at least as
high in heavy infections as in mild infections, but post-treatment
egg counts as an absolute measure tended to be higher in people
with high intensity infections. This pattern persisted at later time
points.
Clinical resolution
At eight weeks the proportion of patients with persistent haema-
turia (defined as > 5 erythrocytes/mL) was lower in those given
praziquantel than placebo in one small trial which reported this
(RR 0.53, 95% CI 0.33 to 0.84; 119 participants, one trial, Anal-
ysis 1.2). There were substantial reductions in the mean number
of erythrocytes in the urine in three trials at one to two months,
but we could not combine these data in a meta-analysis (357 par-
ticipants, three trials, see Appendix 3).
Proteinuria was reduced by 65% to 84% at one to two months
after praziquantel compared to increases in the placebo groups
(238 participants, two trials, see Appendix 3).
Two trials reported mean haemoglobin at baseline and at six to
eight months after treatment with no difference between groups
(mean difference -0.08, 95% CI -0.24 to 0.09; 727 participants,
two trials, Analysis 1.3).
Three trials measured a variety of growth parameters (Befidi
Mengue 1992 CMR; Olds 1999 KEN; Stephenson 1989 KEN).
Two trials reported little or no effect on the outcomes measured
(Befidi Mengue 1992 CMR; Olds 1999 KEN). The third trial
(Stephenson 1989 KEN) reports 14 measures, some of which are
reported as statistically significant, but all appear to be of no or
only borderline clinical importance (see Appendix 4). Most no-
tably, there is a reported increase in children’s physical fitness as
measured by the Harvard Step test. The difference in mean im-
provement between groups was 6.8% at five weeks (mean end
scores 81.2% praziquantel versus 75.5% placebo). Scores between
68% and 82% are considered average. Children that took prazi-
quantel also gained 1.2 kg more weight than those in the control
group, however baseline differences between groups were of a sim-
ilar magnitude to this effect.
Adverse events
Of nine trials, six (with 1286 participants) commented on adverse
events. Only four described the methods used for data collection,
but rarely reported them in detail (see Appendix 5). Adverse events
were usually monitored in the first days after medication. Only
two trials actually reported numbers of adverse events, and only
abdominal pain was reported by both trials. The absolute num-
ber of adverse events was low and none were more common with
praziquantel than placebo (see Analysis 1.4). The other trials sum-
marized narratively with comments such as “both treatments were
well tolerated” (see Appendix 5).
Praziquantel 40 mg/kg versus lower doses (comparison 2)
Praziquantel doses of 20 to 40 mg/kg result in similar reductions in
mean egg excretion, but 40 mg/kg is marginally superior at achieving
cure.
Ten trials compared praziquantel 40 mg/kg with lower doses:
30 mg/kg (seven trials), 20 mg/kg (three trials), and 10 mg/kg
(three trials). All trials were conducted in sub-Saharan Africa in
schoolchildren, apart from one trial, which recruited college stu-
dents and army recruits.
Treatment with praziquantel 40 mg/kg had fewer treatment fail-
ures than lower doses when measured at four to six weeks after
treatment (versus 30 mg/kg; RR 0.76, 95% CI 0.59 to 0.99; 401
participants, four trials, Analysis 2.1, versus 20 mg/kg; RR 0.74,
95% CI 0.59 to 0.93; 338 participants, two trials, Analysis 2.1).
However, there was no difference between 40 mg/kg and 30 mg/
kg at two to three months (517 participants, five trials, Analysis
2.2), or six months after treatment (699 participants, six trials,
Analysis 2.3).
In the five trials comparing praziquantel 40 mg/kg and 30 mg/kg,
the mean number of eggs excreted was reduced by greater than
90% with both doses and without significant differences between
groups (495 participants, five trials, see Table 5).
In trials comparing 40mg/kg and 20mg/kg, again themean num-
ber of eggs excreted was reduced by more than 95% for both doses
and differences in percent egg reduction appeared small (636 par-
ticipants, four trials, see Appendix 2). Treatment with praziquan-
tel 40 mg/kg appeared to result in greater percent egg reductions
than 10 mg/kg (357 participants, three trials, see Appendix 2).
One small trial from Kenya (King 1989 KEN) reported similar
numbers of participants with persistent haematuria or proteinuria
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at three months with praziquantel 40 mg/kg, 30 mg/kg and 20
mg/kg, but 40 mg/kg was superior to 10 mg/kg (haematuria at
three months: RR 0.35, 95% CI 0.21 to 0.58, 119 participants,
one trial, Analysis 2.4; proteinuria at three months: RR 0.25, 95%
CI 0.12 to 0.51; 119 participants, one trial, Analysis 2.5). A larger
trial by the same authors comparing 40 mg/kg and 20 mg/kg
(King 2002 KEN) detected fewer participants with haematuria
at six weeks following praziquantel 40 mg/kg (RR 0.63, 95% CI
0.47 to 0.86; 245 participants, one trial, Analysis 2.6), and fewer
participants with proteinuria (RR 0.66, 95% CI 0.46 to 0.96;
245 participants, one trial, Analysis 2.7). These differences were
still observed at nine months (haematuria: RR 0.59, 95% CI 0.44
to 0.78; 215 participants, one trial, Analysis 2.8; proteinuria RR
0.67, 95%CI 0.5 to 0.9; 214 participants, one trial, Analysis 2.9).
King 2002 KEN also reported ultrasound findings (bladder thick-
ening, bladder irregularity and hydronephrosis) before and after
treatment with praziquantel 40 mg/kg and 20 mg/kg respectively,
but the results were inconclusive (264 participants, see Appendix
6).
Six of these trials did not comment on adverse events. Four trials
described the methods of data collection, but often in insufficient
detail; two out of four trials used active, prospective surveillance
for adverse events (Appendix 5). Two trials stated for all treatment
arms collectively that adverse events after praziquantel treatment
were mild and transient. Two trials reported numbers of adverse
events with no differences between groups (163 participants, Anal-
ysis 3.2).
Praziquantel 40 mg/kg single dose versus split dose
(comparison 3)
Splitting the dose of praziquantel 40 mg/kg into two 20 mg/kg doses
over 24 hours has not been shown to improve tolerability and may
actually cause more vomiting and dizziness.
Three trials compared the single 40 mg/kg dose with a split dose
regimen giving two doses of 20 mg/kg over 24 hours. There was
no statistically significant difference in treatment failure at one
month (RR 0.75, 95% CI 0.51 to 1.11; 374 participants, three
trials), three months (RR 0.74, 95% CI 0.45 to 1.2; 361 partici-
pants, three trials), or six months (RR 0.83, 95% CI 0.51 to 1.35;
234 participants, three trials, Analysis 3.1). Similarly percent egg
reduction was over 90% for both groups (332 participants, three
trials, see Appendix 2).
These trials enrolled 191 participants for a single dose of prazi-
quantel 40 mg/kg and 195 participants for a split dose of 2 x 20
mg/kg. All trials used active surveillance for adverse events (see
Appendix 5). Adverse events were generally reported to be mild
and transient. However one trial reports significantly more vom-
iting and dizziness with the split dose compared to the single dose
(vomiting: RR 0.5, 95%CI 0.29 to 0.86; dizziness: RR 0.39, 95%
CI 0.16 to 0.94; 373 participants, three trials, Analysis 3.2).
Praziquantel 40 mg/kg single dose versus multiple doses
(comparison 4 and 5)
There are too few trials to determine the optimal frequency and timing
of repeated praziquantel dosing.
Two trials compared the standard single dose of praziquantel (40
mg/kg)with twoor three doses given at two or threeweek intervals,
and found no statistically significant differences in parasitological
failure (Analysis 4.1, Analysis 4.2), percentage egg reduction (Ap-
pendix 2), or clinical resolution (Appendix 3; Analysis 4.3).
One additional very small trial from a high transmission setting
in Gabon (van den Biggelaar 02 GAB), compared praziquantel
40 mg/kg every three months for two years to a single dose of
praziquantel 40 mg/kg given at the beginning of the trial. At two
years, patients who received only one dose of praziquantel had
almost three times the risk of treatment failure compared to mul-
tiple doses (RR 2.71, 95% CI 1.47 to 5.00; 62 participants, one
trial, Analysis 5.1). Percent egg reduction was 96% after multiple
doses and 80% after a single dose of praziquantel at two years (90
participants, see Table 6). These effects were no longer apparent
one year after the last praziquantel dose.
These trials did not report on adverse events.
Section B: Metrifonate
Metrifonate single dose versus placebo (comparison 6)
A single dose of metrifonate 10 mg/kg probably reduces egg excretion
but is only marginally better than placebo at achieving cure.
Two trials compared a single dose of metrifonate to placebo, al-
though one trial only reported outcomes at a single time point
eight months after treatment (Stephenson 1989 KEN).
In the first trial (Pugh 1983 MWI), 80% of those treated with
metrifonate continued to excrete eggs one month after treatment
which was only marginally better than placebo (RR 0.83, 95%
CI 0.74 to 0.94; 142 participants, one trial, Analysis 6.1), and no
difference was seen at six months (RR 0.94, 95% CI 0.87 to 1.02;
102 participants, one trial, Analysis 6.1).
In the second trial (Stephenson 1989 KEN), 61% of those treated
with metrifonate continued to excrete eggs eight months after
treatment compared with almost 100% who received placebo (RR
0.63, 95% CI 0.54 to 0.73, 210 participants, one trial, Analysis
6.1). Egg excretion was also reduced by more than 90% eight
months after treatment compared to just 5% with placebo (210
participants, see Appendix 2).
The second trial also reported mean haemoglobin at baseline and
eight months (with no difference between groups, Analysis 6.2),
and various measures of nutrition and growth (see Appendix 4).
However, this trial had three arms and the nutritional measures are
reported for the metrifonate and praziquantel groups combined.
Consequently, wewere unable to evaluate the effect ofmetrifonate.
Trial authors did not report adverse events.
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Metrifonate multiple doses versus placebo (comparison 7)
Subsequently trials evaluated multiple doses of metrifonate given two
weeks apart, which improved the proportion of patients being cured.
Two trials evaluated three doses of metrifonate 7.5 mg/kg given
two weeks apart (Jewsbury 1976 ZWE; Stephenson 1985 KEN),
and reported much reduced treatment failures compared to
placebo at 11 weeks (RR 0.41, 95% CI 0.30 to 0.56; 93 partic-
ipants, one trial, Analysis 7.1) and six months respectively (RR
0.30, 95% CI 0.24 to 0.37; 400 participants, one trial, Analysis
7.1).
A third small trial (de Jonge 1990 SDN) comparing two 10 mg/kg
doses given two weeks apart with placebo found very low levels of
cure and no difference compared to placebo at one month or five
months (51 participants, one trial, Analysis 7.1). However, this is
the same trial that found very high levels of treatment failure with
praziquantel, which may be a result of the highly sensitive method
used for detecting low level egg excretion and the strict definition
of cure.
All three trials found substantial reductions in the number of eggs
being excreted at their various time points (> 90% reductions in
all three trials, see Table 7).
Stephenson 1985 KEN also reported mean haemoglobin, with
slightly higher values at six months after metrifonate compared
to placebo (mean difference 0.3 G/dL, 95% CI 0.14 to 0.46;
400 participants, one trial, Analysis 7.2). The authors noted that
hookworm endemicity was high, andmetrifonate also has an effect
on hookworm which could account for this finding.
None of the trials reported on adverse events.
Direct comparisons of different metrifonate regimens
(comparisons 8 and 9)
In one trial, multiple doses of 10 mg/kg were superior to a single dose.
One three-arm trial directly compared a single dose of 10 mg/
kg with two or three doses given two weeks apart. Parasitological
failure at one month was 53% with a single dose, 40% with two
doses, and 19% with three doses. The difference was statistically
significant for three doses versus one dose (RR 0.36, 95% CI
0.17 to 0.77; 93 participants, one trial, Analysis 8.1), but not
two doses versus one dose (RR 0.75, 95% CI 0.5 to 1.13; 112
participants, one trial, Analysis 8.1). Results were similar at four
months (Analysis 8.2).
The percent egg reduction was also improved from 37% after a
single dose to 88% after three doses, although this was not main-
tained at the four months’ follow-up (see Appendix 2). This trial
did not report on adverse events.
One additional trial (Abden Abdi 1989 SOM) compared three
doses of 7.5 mg/kg given two weeks apart with three doses of
5 mg/kg given in one day. The trial detected no difference for
parasitological failure at one month, three months or six months
(201 participants, one trial, Analysis 9.1). Egg reduction at one
month was above 90% after both metrifonate doses and was sus-
tained (> 90%) at two, three and six months (201 participants, see
Appendix 2). This trial recorded adverse events by active surveil-
lance (Appendix 5). It did not detect a significant difference for
any of the symptoms between treatment groups (201 participants,
one trial, Analysis 9.2) The adverse events were mild and tran-
sient.Headache and abdominal pain were most common.
Section C: Praziquantel versus metrifonate
Praziquantel 40 mg/kg single dose versus metrifonate 10
mg/kg single dose (comparison 10)
Single dose praziquantel 40 mg/kg was more effective than single dose
metrifonate 10 mg/kg in curing patients and reducing egg excretion.
Three trials compared the standard dose of praziquantel 40 mg/kg
with a single dose of metrifonate 10mg/kg, although one trial only
reported outcomes at eight months after treatment (Stephenson
1989 KEN).
In the first trial (Pugh 1983 MWI), parasitological failure at one
month was halved with praziquantel 40 mg/kg compared to met-
rifonate 10 mg/kg (RR 0.46, 95% CI 0.34 to 0.61; 183 partic-
ipants, one trial, Analysis 10.1). Treatment failure increased in
both groups over the following five months which the authors sus-
pect was due to egg excretion by maturing worms, as transmission
and re-infection were low in the trial setting (Analysis 10.1). The
second trial (Wilkins 1987 GMB), also found praziquantel to be
superior to metrifonate at two to three months as its only time
point (RR 0.45, 95% CI 0.27 to 0.75; 72 participants, one trial,
Analysis 10.1).
The third trial (Stephenson 1989 KEN), found substantial reduc-
tions in both treatment failure (RR 0.21, 95% CI 0.13 to 0.36;
208 participants, one trial, Analysis 10.1) and egg excretion (see
Appendix 2), with praziquantel compared tometrifonate.Haemo-
globin levels measured in this trial were higher in the praziquantel
treatment arm both at baseline and at follow-up (208 participants,
one trial, Analysis 10.2). The trial did not detect a difference in
growth parameters between groups but does not report them sep-
arately (see Appendix 4).
None of the trials reported on adverse events.
Praziquantel 40 mg/kg single dose versus multiple doses of
metrifonate 10 mg/kg
Two small trials found no difference in parasitological treatment fail-
ure or egg excretion between single dose praziquantel 40 mg/kg and
two or three doses of metrifonate 10 mg/kg.
Two small trials compared praziquantel 40 mg/kg single dose to
two and three doses of metrifonate 10 mg/kg given two weeks
apart. The trials detected no difference in parasitological treatment
failure at different time points and with different metrifonate reg-
imens. However, in one trial both drugs performed poorly (de
Jonge 1990 SDN), and in one trial both performed well (Al Aska
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1990 SAU) (see Analysis 10.3). The trial where both drugs per-
formed poorly for parasitological failure has been discussed above
and this is likely to be due to the very sensitive method for detect-
ing eggs. In this trial, both drugs reduced mean egg excretion by
over 98% at one month and five months (see Appendix 2), and a
decrease in haematuria by over 90% at one month. Reduction in
proteinuria was almost 80% in both groups (see Appendix 3).
Only Al Aska 1990 SAU reported adverse events; dizziness was
more common after praziquantel (RR 2.9, 95% CI 1.59 to 5.3;
100 participants, one trial, Analysis 10.4). Dizziness (20% in the
praziquantel group and 10% in the metrifonate group) and ab-
dominal pain (12% both in the praziquantel and metrifonate
group) were the most common side effects (Appendix 5).
Additional comparisons of praziquantel and metrifonate
One small trial compared a single dose of praziquantel 30 mg/
kg to three doses of metrifonate 10 mg/kg given two weeks apart
and found no difference in parasitological failure at two months,
but a statistically significant difference in favour of praziquantel at
four months (RR 0.24, 95% CI 0.07 to 0.8; 52 participants, one
trial, Analysis 10.5). Egg reduction at four months was above 98%
in both treatment groups (Appendix 2). In this trial, abdominal
pain was more common in the metrifonate group (RR 0.33, 95%
CI 0.12 to 0.92; 60 participants, one trial, Analysis 10.6), while
no difference was detected for the eight other clinically diagnosed
symptoms reported.
One large population-based trial from Kenya compared prazi-
quantel 40 mg/kg given once a year to metrifonate 10mg/kg given
three times a year. After one year, this trial detected no difference
in treatment failure, haematuria or proteinuria (1400 participants,
one trial, Analysis 10.7), but mean egg excretion was reduced by
over 80% in both groups at one year (Appendix 2). There con-
tinued to be no difference in parasitological failure at two years,
but praziquantel was superior in the third year (RR 0.62, 95%
CI 0.42 to 0.93; 827 participants one trial, Analysis 10.8). Ultra-
sound findings, recorded in a sub-sample of children, were incon-
clusive (373 participants, Appendix 6).
One further small trial compared a single dose of praziquantel 40
mg/kg with a combination of praziquantel 10 mg/kg and metri-
fonate 10 mg/kg. At two to three months there was no difference
in treatment failure (72 participants, one trial, Analysis 10.9). Per-
cent egg reduction was 99.4% after praziquantel alone and 92.9%
after the combination treatment (see Appendix 2).
Section D: Artesunate
Artesunate versus placebo (comparison 11)
The two placebo controlled trials of artesunate had inconsistent results,
and the single trial at low risk of bias found only a modest effect on
egg excretion compared to placebo.
Two trials compared artesunate 4 mg/kg once daily for three days
with placebo. The two trials had inconsistent results on parasito-
logical failure, with one trial finding no difference between arte-
sunate and placebo, and one finding lower treatment failures with
artesunate at eight weeks (251 participants, two trials, Analysis
11.1). The trial finding an effect was at unclear risk of both selec-
tion and detection bias due to an inadequate description of trial
methods (Inyang Etoh 2009 NGA).
Both trials found that artesunate reduced egg excretion compared
to placebo (Table 8), but the percent reduction was low compared
to that seen in placebo controlled trials of praziquantel (percent
egg reductions of between 52% and 69%).
The trial at unclear risk of bias also reported improved reductions
in haematuria and proteinuria compared to placebo, while the
trial at low risk of bias (Borrmann 2001 GAB) found no effect
on proteinuria (see Appendix 3). No differences in adverse events
were reported (see Appendix 5, Analysis 11.3).
Praziquantel versus artesunate (comparison 12)
The results of the three trials are inconsistent, with the single trial at
low risk of bias finding only a modest reduction in egg excretion with
artesunate.
Three trials (Borrmann 2001 GAB; Inyang Etoh 2009 NGA;
Keiser 2010 CIV) compared artesunate 4 mg/kg/d for three days
with praziquantel 40 mg/kg single dose.
The three trials had mixed results. In two trials artesunate per-
formed poorly, with parasitological treatment failures of over 70%
at onemonth and twomonths respectively (Borrmann 2001GAB;
Keiser 2010 CIV). In these trials praziquantel was clearly superior
(Analysis 12.1). In the third trial (Inyang Etoh 2009 NGA), at
unclear risk of bias due to inadequate description of trial methods,
artesunate performed similarly to praziquantel with 28% treat-
ment failures at two months (Analysis 12.1).
The percent egg reduction with artesunate varied across the three
trials from 52% to 85% (see Appendix 2). In the single trial where
both praziquantel and artesunate performedwell at reducing treat-
ment failures, both drugs had fairly modest effects on egg excre-
tion (Inyang Etoh 2009 NGA).
Only the trial at unclear risk of bias (Inyang Etoh 2009 NGA)
reported substantial effects of artesunate on haematuria and pro-
teinuria (see Appendix 3). In the trial at low risk of bias (Borrmann
2001 GAB) praziquantel was clearly superior at reducing micro-
hematuria (RR 0.43, 95% CI 0.3 to 0.62; 178 participants, one
trial, Analysis 12.2).
All trials reported on adverse events with no significant differences
noted between groups (see Appendix 5, Analysis 12.3).
Praziquantel versus praziquantel plus artesunate
(comparison 13)
The results of the two trials were inconsistent but the trial at low risk
of bias found no benefit with adding artesunate to praziquantel.
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Two of the trials comparing artesunate with praziquantel also had
a treatment arm where patients received both drugs (Borrmann
2001GAB; Inyang Etoh 2009 NGA). Again, in the trial at low risk
of bias (Borrmann 2001 GAB) adding artesunate to praziquantel
did not substantially reduce treatment failures or percent egg re-
duction at eight weeks compared to praziquantel alone, whereas in
the trial at unclear risk of bias (Inyang Etoh 2009 NGA), adding
artesunate improved outcomes (Analysis 13.1; Table 9; Appendix
2). No differences in adverse events were reported (see Appendix
5).
Section E: Others
Mefloquine versus sulfadoxine-pyrimethamine (comparison
14)
In a single trial comparing the use of mefloquine and sulfadoxine-
pyrimethamine as intermittent preventive treatment for malaria
in pregnancy, a re-analysis of the small number of mothers in-
fected with S. haematobium found more women were cured at one
month after mefloquine compared to sulfadoxine-pyrimethamine
(RR 0.57, 95% CI 0.4 to 0.83; 44 participants, one trial, Analysis
14.1), and an egg reduction of 80% four weeks after treatment
and 98% ten weeks after treatment (see Appendix 2).
Praziquantel versus mefloquine alone or mefloquine in
combination with artesunate (comparison 15 and 16)
A single small trial (Keiser 2010 CIV) reported lower treatment
failures with praziquantel 40 mg/kg alone than with mefloquine
25 mg/kg (RR 0.15, 95% CI 0.05 to 0.43; 45 participants, one
trial, Analysis 15.1) or with mefloquine in combination with arte-
sunate 4 mg/kg/d for three days (RR 0.23, 95% CI 0.07 to 0.74;
44 participants, one trial, Analysis 16.1). At four weeks, this trial
reports a percent egg reduction of 74% at four weeks with meflo-
quine alone (19 participants), 96% with mefloquine and arte-
sunate combined, and 97% with praziquantel (Appendix 2).
Keiser 2010 CIV recorded adverse events by active, prospective
surveillance. Adverse events were mild to moderate and common
in all groups. There were no statistically significant differences in
any individual adverse event (Appendix 5).
Praziquantel versus praziquantel and albendazole
(comparison 17)
One trial (Olds1999KEN) compared a single dose of praziquantel
40 mg/kg with a combination of single dose praziquantel 40 mg/
kg plus albendazole 400mg at day 45 (RR0.9, 95%CI 0.62 to 1.3;
193 participants, one trial, Analysis 17.1). The authors concluded
that albendazole does not influence the effect of praziquantel.
Adverse events were monitored by active, prospective surveillance
and described as mild and transient. Diarrhoea, headache and
abdominal pain were observed most frequently, but adverse events
were reported for participants treated for S. haematobium and S.
mansoni together (Appendix 5).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Praziquantel 40 mg/kg compared to praziquantel 30 mg/kg for treating urinary schistosomiasis
Patient or population: people with urinary schistosomiasis
Settings: endemic areas in Sub-Saharan Africa
Intervention: praziquantel 40 mg/kg (single dose)
Comparison: praziquantel 30 mg/kg (single dose)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Praziquantel 30 mg/kg single
dose
Praziquantel 40 mg/kg single
dose
Parasitological failure
At 1 month
32 per 100 24 per 100
(19 to 32)
RR 0.76
(0.59 to 0.99)
401
(4 trials)
⊕⊕©©
low1,2,3,4
Mean percent egg reduction
At 1 month
The mean reduction in control
groups ranged from an 85%
reduction to a 99% reduction.
The mean reduction in the in-
tervention groups was>95%
in all trials
Not pooled 362
(4 trials)
⊕⊕©©
low1,3,5,6
Parasitological failure
At 6 months
29 per 100 28 per 100
(22 to 36)
RR 0.97
(0.76 to 1.23)
669
(6 trials)
⊕⊕⊕©
moderate
1,3,7,8
Mean percent egg reduction
At 6 months
The mean reduction in control
groups ranged from an 97%
reduction to a 99% reduction.
The mean reduction in the in-
tervention groups ranged from
a 46% reduction15 to a 99%
reduction
Not pooled 362
(4 trials)
⊕⊕©©
low1,3,9,10
Haematuria 26 per 100 23 per 1000
(12 to 44)
RR 0.89
(0.47 to 1.67)
117
(1 trial)
⊕©©©
very low11,12,13
Proteinuria 15 per 100 13 per 100
(5 to 31)
RR 0.85
(0.34 to 2.12)
117
(1 trial)
⊕©©©
very low 11,12,131
9
D
ru
g
s
fo
r
tre
a
tin
g
u
rin
a
r
y
sc
h
isto
so
m
ia
sis
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
4
T
h
e
A
u
th
o
rs.
T
h
e
C
o
c
h
ra
n
e
D
a
ta
b
a
se
o
f
S
y
ste
m
a
tic
R
e
v
ie
w
s
p
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
o
n
b
e
h
a
lf
o
f
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
Adverse events - - Not estimable 992
(8 trials)
⊕⊕©©
low14
*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk
in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded by 1 for serious risk of bias: None of the trials described a method of allocations concealment or blinding outcome
assessors.
2 No serious inconsistency: No statistical heterogeneity in the relative effect of the two praziquantel doses. However, treatment failure
with praziquantel 40 mg/kg ranged from 0% to than more than 50%.
3 No serious indirectness: All trials were conducted in sub-Saharan Africa, in patients aged from seven to 20 years.
4 Downgraded by 1 for serious imprecision: None of the individual studies found statistical significant differences, and overall, the meta-
analysis remains underpowered to confidently detect an effect.
5 No serious inconsistency: Three of the four trials report the difference was not statistically significant. The fourth trial did not report
significance but effects were similar.
6 Downgraded by 1 for serious imprecision: We were unable to pool the data, and as such cannot exclude a small difference in effect
between the two doses in a pooled analysis.
7 No serious inconsistency. Low statistical heterogeneity.
8 No serious imprecision. The effect is of no clinically important difference between the two doses, and the 95% CIs are narrow.
9 Downgraded by 1 for serious inconsistency: In one trial praziquantel 40 mg/kg had a very low percent egg reduction of 46%. The
reasons for this are unclear.
10 Unable to assess precision as the data were not pooled.
11 Downgraded by 1 for serious risk of bias: This trial did not adequately describe allocation concealment. Participants and clinicians
were not blinded.
12 Downgraded by 1 for serious indirectness: Only one trial from one setting.
13 Downgraded by 1 for serious imprecision. This trial is underpowered to detect an effect. The 95% CI is wide and includes clinically
important benefits and no effect.
14 Downgraded by 2 for serious risk of bias. Six out of ten trials comparing praziquantel 40 mg/kg to lower doses did not comment on
adverse events, and of the remaining only two used prospective active surveillance to monitor adverse events. Only two trials out of ten
described blinding for clinicians or participants.
2
0
D
ru
g
s
fo
r
tre
a
tin
g
u
rin
a
r
y
sc
h
isto
so
m
ia
sis
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
4
T
h
e
A
u
th
o
rs.
T
h
e
C
o
c
h
ra
n
e
D
a
ta
b
a
se
o
f
S
y
ste
m
a
tic
R
e
v
ie
w
s
p
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
o
n
b
e
h
a
lf
o
f
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
Praziquantel 40 mg/kg multiple doses compared to single dose for treating urinary schistosomiasis
Patient or population: patients with treating urinary schistosomiasis
Settings: endemic settings
Intervention: Praziquantel 40 mg/kg multiple doses (every three months for two years)
Comparison: Praziquantel 40 mg/kg single dose
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Praziquantel 40 mg/kg
single dose
Praziquantel 40 mg/kg
multiple doses
Parasitological failure
At 2 years
90 per 100 244 per 100
(132 to 450)
RR 2.71
(1.47 to 5.00)
62
(1 trial)
⊕©©©
very low1,2,3,4
Mean percent egg re-
duction
At 2 years
This study reports a81%
reduction after a single
dose of praziquantel
This study reports a96%
reduction after multiple
doses of praziquantel
- 62
(1 trial)
⊕©©©
very low1,2,3,4
Parasitological failure
At 3 years
63 per 100 56 per 100
(37 to 89)
RR 0.92
(0.59 to 1.42)
43
(1 trial)
⊕©©©
very low1,2,3,4
Haematuria
At 3 years
48 per 100 34 per 100
(20 to 56)
RR 0.7
(0.42 to 1.17)
43
(1 trial)
⊕©©©
very low1,2,3,4
Adverse events - This study reports a96%
reduction after multiple
doses of praziquantel
- 43
(1 trial)
⊕©©©
very low5
*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk
in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded by 2 for serious risk of bias. The one trial reporting the outcome did not report adequately on sequence generation and
blinding. Allocation was not concealed, and loss to follow up was very high.
2 No serious inconsistency: only one trial.
3 No serious indirectness: only one trial.
4 Downgraded by 1 for serious imprecision: This single trial is small and underpowered to reliably detect an effect.
5 This trial did not report on adverse events.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Metrifonate compared to placebo for treating urinary schistosomiasis
Patient or population: patients with treating urinary schistosomiasis
Settings: endemic settings
Intervention: metrifonate 3 x 7.5 mg/kg given two weeks apart
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Placebo Metrifonate 3 x 7.5 mg/kg
given two weeks apart
Parasitological failure
At 2 to 2.5 months
40 per 100 16 per 100
(12 to 22)
RR 0.41
(0.3 to 0.56)
93
(1 trial)
⊕⊕©©
low1,2,3,4
Mean percent egg reduction
At 2 to 2.5 months
Egg excretion increased by
131% in the placebo group in
this study
Egg excretion was reduced by
100% in this trial
- 93
(1 trial)
⊕⊕©©
low1,2,3,4
Parasitological failure
At 6 months
96 per 100 29 per 100
(23 to 36)
RR 0.3
(0.24 to 0.37)
400
(1 trial)
⊕⊕⊕©
moderate2,3,5,6
Mean percent egg reduction
At 6 months
13% increase 94% reduction - 400
(1 trial)
⊕⊕⊕©
moderate2,3,5,7
Adverse events - - - 493
(2 trials)
8
*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk
in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded by 1 for serious risk of bias; the single trial reporting this outcome did not adequately describe sequence generation,
allocation concealment and blinding of participants, clinicians or outcome assessors.
2 No serious inconsistency. Only one trial.
3 No serious indirectness. This single trial was conducted in children in rural sub-Saharan Africa.
4 Downgraded by 1 for serious imprecision. The trial was underpowered.
5 Downgraded by 1 for serious risk of bias. The trial did not report on sequence generation and allocation concealment. The study
described blinding of participants, clinicians and outcome assessors.
6 No serious imprecision. CIs are narrow and both CI limits have clinically important effects. The trial is adequately powered for this
outcome.
7 No serious imprecision. The difference in effect between metrifonate and placebo group is large.
8 None of the trials reported on adverse events.
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Artesunate compared to placebo for treating urinary schistosomiasis
Patient or population: patients with treating urinary schistosomiasis
Settings: endemic settings
Intervention: artesunate 4 mg/kg for three days
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Placebo Artesunate
Parasitological failure
At 8 weeks
87 per 100 46 per 100
(14 to 148)
RR 0.53
(0.16 to 1.71)
251
(2 trials)
⊕⊕©©
very low1,2,3,4
Mean percent egg reduction
At 8 weeks
Mean change in egg excretion
ranged from range from 47.
1% reduction to 111.5% in-
crease.
Reduction in egg excretion
ranged from 52.1% to a 69.
3%
- 276
(2 trials)
⊕©©©
low1,3,5,6
Microhaematuria
At 8 weeks
53 per 100 65 per 100
(45 to 94)
RR 1.22
(0.85 to 1.76)
119
(1 trial)
⊕⊕©©
low 7,8,9,10
Adverse events - - - 276
(2 trials)
⊕⊕©©
low11,12
*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk
in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.25
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1 Downgraded by 1 for serious risk of bias. One trial described sequence generation, allocation concealment and blinding adequately,
whereas the second study did not.
2 Downgraded by 1 for serious inconsistency. One of the trials (at high risk of bias) reported a large effect, while the other trial (at low
risk of bias) detected no effect.
3 No serious indirectness. The trials were conducted in Gabon and Nigeria in patients of a similar age range.
4 Downgraded by 1 for serious imprecision. The CI is very wide and reaches from no benefit to a significant benefit after treatment.
5 No for serious inconsistency. Percent egg reductions the studies reported were similar.
6 Downgraded by 1 for serious imprecision. The meta analysis is underpowered.
7 No serious risk of bias. The one trial reporting the outcome reported adequately on sequence generation, allocation concealment and
blinding.
8 No serious inconsistency: only one trial.
9 No serious indirectness: This trial was conducted in school children in Gabon.
10 Downgraded by 2 for very serious imprecision: only one trial reporting 74 events in 119 participants evaluated this outcome.
11Downgraded by 1 for serious risk of bias: only one trial was blinded. Both trials reported on adverse events, but the methods are
unclear.
12 Downgraded by 1 for imprecision. One study reported on clinically diagnosed outcomes per treatment group, but was underpowered
to confidently detect a difference.
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Praziquantel plus artesunate compared to praziquantel alone for treating urinary schistosomiasis
Patient or population: patients with urinary schistosomiasis
Settings: Countries endemic for urinary schistosomiasis
Intervention: Praziquantel plus artesunate
Comparison: Praziquantel alone
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Praziquantel 40 mg/kg single
dose alone
Praziquantel 40 mg/kg single
dose plus artesunate 4 mg/
kg/d for 3 days
Parasitological failure at 8
weeks
27 per 100 17 per 100
(10 to 27)
RR 0.62 (0.38 to 0.99) 265
(2 trials)
⊕⊕©©
low1,2,3,4
Percent egg reduction Egg reduction in the Prazi-
quantel groups ranged from
52.1% reduction to a 97.11%
reduction.
Egg reduction in the Praz-
iquantel and ARS groups
ranged from 93.5% to 98.8%
- 265
(2 trials)
⊕©©©
very low1,2,5,6
Microhaematuria 28 per 100 19 per 100
(11 to 33)
RR 0.69
(0.4 to 1.18)
177
(1 trial)
⊕⊕©©
low7,8
Adverse events - - - 156
(1 trial)
⊕©©©
very low 9,10
*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk
in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded by 1 for serious risk of bias: only one out of two studies did report adequate random sequence generation, allocation
concealment and blinding or participants and clinicians, while the other study did not provide enough information to allow a judgement.
2 No serious inconsistency. Both studies favour the combination of Praziquantel and ARS over Praziquantel alone.
3 No serious indirectness. The trials were conducted in rural communities in Gabon and Nigeria, in children (6 to 15 years) and young
adults (4 to 20 years)
4 Downgraded by 1 for serious imprecision: Only two studies were included in this comparison. The effect size, described by the 95% CI
ranged from a very small, clinically non-important effect to a clinically important effect.
5 Downgraded by 1 for serious inconsistency: egg reduction varied widely between the two trials.
6 Downgraded by 1 for serious imprecision: Only two studies reported this outcome.
7 No serious risk of bias. The one study that reporting this outcome described adequate random sequence generation, allocation
concealment and blinding.
8 Downgraded by 2 for serious imprecision: only one small study reported this outcome, the outcome is not statistically significant with
wide 95% CI.
9 Downgraded by 2 for serious risk of bias. This study did not provide enough information to allow a judgement regarding sequence
generation, allocation concealment and blinding.
10Downgraded by 1 for serious imprecision. Only one study reported on adverse events. The study was underpowered, and no difference
in adverse events was detected between treatment groups.
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D I S C U S S I O N
For a summary of the main results of the review and GRADE
assessment of the quality of evidence see: Summary of findings
for the main comparison; Summary of findings table 2; Summary
of findings 2; Summary of findings 3; Summary of findings 4;
Summary of findings 5; and Summary of findings 6.
Summary of main results
On average, a single 40 mg/kg dose of praziquantel reduced the
proportion of people still excreting S. haematobium eggs in their
urine by around 60% compared to placebo at one to two months
after treatment (high quality evidence), and reduced themean num-
ber of schistosome eggs in the urine by over 95% in five out of
six trials (high quality evidence). Splitting praziquantel 40 mg/kg
into two doses over 12 hours probably has no benefits over a single
dose.
Two small trials compared a single 40 mg/kg dose of praziquantel
with two or three doses of 10 mg/kg metrifonate and found no
differences in cure. In one trial both drugs performed badly and
in one trial both performed well.
Three trials evaluated the antimalarial artesunate, and two trials
evaluated mefloquine, with inconsistent results.
Overall completeness and applicability of
evidence
The WHO currently recommend that schistosomiasis is treated
with a single dose of praziquantel of at least 40 mg/kg (WHO
2006). In this review we found no trials evaluating doses higher
than 40 mg in urinary schistosomiasis, but doses of 40 mg/kg or
even 30mg/kg are effective at reducing egg excretion and achieving
cure.
Of all the drugs that have been evaluated for treating urinary schis-
tosomiasis, praziquantel has by far the strongest evidence base. It
has been evaluated across a wide range of endemic countries, and
most trials were conducted in children who bear the highest bur-
den of disease. However, few trials included children younger than
five years of age, and Stothard 2013 suggested that higher doses
of praziquantel might be required for this group. We would have
liked to explore this possibility through an analysis stratified by
age, but the data did not allow this and no firm conclusions can
be made. In addition, most trials concentrated on parasitological
efficacy, and few reported clinical outcomes such as improvement
in haematuria or anaemia. Data on resolution of long-term mor-
bidity after treatment, as nutritional outcomes and sonographic
findings are very rare, and follow-up is limited to less than one
year.
The absolute proportion of people cured by praziquantel varied
between trials while percent egg reduction was relatively homoge-
nous. This may be explained by low sensitivity and negative pre-
dictive value of the diagnostic test, compounded with the fact that
egg yield varies during the day and with physical activity. This
means that patients with few eggs in their urine may be variably
declared as positive or negative in different settings. The propor-
tional reduction in the mean egg counts from before to after treat-
ment is less prone to this error. It also appears that some trials
based post-treatment egg reduction on the whole trial population
(including cured patients with zero egg counts), while other trials
based the post-treatment calculations on those patients still ex-
creting eggs. We were unable to combine egg reduction values in
meta-analysis, and assess statistical significance, due to the poor
reporting of standard deviations and methods for calculating the
mean (Table 2).
None of the included trials suggested drug resistance as a possi-
ble cause of high parasitological failure, or of recurrent schistoso-
miasis over prolonged follow-up. In high transmission areas two
mechanisms could explain rising parasitological failure over time:
maturation of immature worms (which escape the action of praz-
iquantel) to egg producing adults, and reinfection.
Previously theWHO also recommendedmetrifonate at 7.5mg/kg
for three doses (given twoweeks apart), but this drug is now largely
unavailable (Danso-Appiah 2008). We found some evidence that
repeated doses of metrifonate had reasonable antischistosomal ef-
fects but we found no trials directly comparing this dose with the
standard dose of praziquantel. Combining praziquantel with met-
rifonate is one possible strategy for improving parasitological cure
as they attack S. haematobium by different mechanisms (Utzinger
2004). However, we only found one small trial evaluating a com-
bination approach and this used a low dose of praziquantel rather
than the standard 40 mg/kg (Wilkins 1987 GMB).
Antimalarials (such as artesunate andmefloquine) given alone or in
combination with praziquantel are another potential future treat-
ment option, but the current evidence base is limited to a few
trials with inconsistent results. As many locations in sub-Saharan
Africa are co-endemic for schistosomiasis and malaria, there are
also concerns about development of Plasmodium parasite resis-
tance to artemisinins, especially as they would be used in a single
dose and without a companion antimalarial drug (Utzinger 2004).
Any change in policy would need to fully consider this potential
public health harm.
Quality of the evidence
We used the GRADE approach to assess the quality for the evi-
dence.
We consider the evidence for substantial benefits with praziquan-
tel compared to placebo to be of high quality, meaning we have
confidence in this result. Many of the included trials are old, but
reassuringly the findings of the most recent trial conducted in
2005/2006 are consistent with the older studies.
However, we consider most of the evidence for other comparisons
in this review to be of low or even very low quality. Most of the
29Drugs for treating urinary schistosomiasis (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
trials evaluating metrifonate are old and precede guidelines on
transparent reporting of clinical trials. As such, many trials lacked
adequate descriptions of methods to allow judgements on risk of
bias, and so risk of bias has been classified as unclear. Trials were
also generally small and underpowered to reliably detect or exclude
effects.
Of the three trials reporting on the antischistosomal effects of
artesunate, only one was at low risk of bias and this trial found
little effect with artesunate compared to placebo (Borrmann 2001
GAB). Although the metanalysis suggests artesunate may improve
cure when added to praziquantel, this evidence was of low quality
due to inconsistency between trials, and the single trial showing a
large effect being at unclear risk of bias for all domains.
Potential biases in the review process
Our information specialist followed a detailed, reproducible search
strategy, and we searched reference lists of included trials. How-
ever, some trials might not be available online, and therefore an
electronic search will not identify them.
In many cases, clarification of information with authors was not
possible as no contact e-mail addresses were available as the trials
were very old.
Agreements and disagreements with other
studies or reviews
Two recent systematic reviews evaluated the use of artemisinins in
treating urinary schistosomiasis (Liu 2011; Pérez del Villar 2012),
and both concluded that the combination of artesunate plus praz-
iquantel is superior to praziquantel alone, While we find some
evidence to support this we conclude that this evidence is only
of low quality and encourage further high quality and adequately
powered trials before any change in treatment policy. Of note, the
trial at lowest risk of bias (Borrmann 2001 GAB), found no sig-
nificant difference in cure between artesunate alone and placebo,
or between praziquantel plus artesunate and praziquantel alone.
One further systematic review evaluated single or repeated doses
of praziquantel, and found no evidence of benefit with repeated
dosing compared to a single dose in people with S. haematobium
infection (King 2011). We would agree that repeating doses two
or three weeks apart does not seem to provide benefit over a single
dose based on two trials with 686 participants. However, repeating
doses at threemonthly intervals over two years did seem to provide
some additional benefits in a single small trial and further trials
could evaluate this.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Praziquantel is the most studied drug for treating urinary schis-
tosomiasis and has the strongest evidence base. Although there
is some evidence that 30 mg/kg may be sufficient, operationally
this would prove difficult as 40 mg/kg is used to treat people with
intestinal schistosomiasis, and the two diseases often overlap.
Implications for research
Potential strategies to improve future treatments for schistosomi-
asis include the combination of praziquantel with metrifonate, or
with antimalarials with antischistosomal properties such as arte-
sunate and mefloquine. Evaluation of these combinations requires
rigorous. adequately powered trials using standardized outcome
measures. It is both important and urgent that these parameters
be agreed upon and applied. Trial protocols with standardised di-
agnostic methods, time points of follow-up and efficacy outcomes
would enable us to combine trials in meta-analysis and to reduce
heterogeneity between trials.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abden Abdi 1989 SOM
Methods RCT
Diagnostics: egg excretion in a single, mid-day urine sample, mixing an aliquot of 10
mL urine, filtration (nucleopore)
Follow-up at 1, 2, 3 and 6 months
Participants Children aged 11 to 12 years on average
Number randomized 300
Number analysed for primary outcome at one month 201, at six months 139
Inclusion criteria: excreting 20 or more S. haematobium eggs per 10 mL urine
Exclusion criteria: concomitant disease
Interventions 1. Metrifonate 3 x 7.5 mg/kg dose interval two weeks
2. Metrifonate 3 x 5 mg/kg within one day
3. Placebo
Outcomes Cure rate
Percentage egg reduction
Adverse events
Notes Location: Somalia, southern part
Setting: rural, five villages
Endemicity: high
Dates: not stated
Source of funding: SAREC (Swedish agency for research cooperation with developing
countries)
Authors’ conclusion: Both metrifonate regimens have similar efficacy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomized, randomly assigned, table of
random numbers.
Allocation concealment (selection bias) Low risk All doses were kept in coded envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind, placebo controlled “and the
distributor of the drug and the participants
were all blind to the type of treatment.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of the lab technician.
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Abden Abdi 1989 SOM (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk High loss to follow-up, 33% at one month,
53%at sixmonths, balanced between treat-
ment arms
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk No evidence of other bias.
Al Aska 1990 SAU
Methods RCT
Diagnostics: ova excretion in 10 mL midday urine after sedimentation
Follow-up: three and six months
Participants Adult patients referred to hospital, age not stated. Saudi and Jemeni
Number randomized: not reported
Number analysed: 100
Inclusion criteria: S. haematobium infection
Exclusion criteria: none stated
Co-infection with S. mansoni
Interventions 1. Praziquantel 40 mg/kg single dose
2. Metrifonate 10 mg/kg three doses in intervals of two weeks
Outcomes Cure rates
Failure rates
Notes Location: Saudi Arabia
Setting: King Abdul Aziz University hospital, Riyadh. Patient referral
Endemicity: not reported
Dates: not stated
Funding: not stated
Authors’ conclusion: Metrifonate and praziquantel in the stated dosage are effective
against S. haematobium, side effectives are minor and transient
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “allocated randomly”.
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not mentioned, no placebo mentioned.
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Al Aska 1990 SAU (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up not reported.
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk Few baseline characteristics reported.
Basra 2012 GAB
Methods RCT
Diagnostics: Ova excretion, microscopy in 10 mL urine after filtration, AMEC
Follow-up: six weeks
Participants Pregnant women attending ANC clinics, aged 19 to 25 years
Number randomized 65
Number analysed 44
Inclusion criteria: S. haematobium infection, pregnancy
Exclusion criteria: intake of antihelminthic and antimalarial drug within the previous
two months, HIV pos
Interventions 1. Praziquantel 40 mg/kg single dose
2. Metrifonate 10 mg/kg two doses, dose interval two weeks
Outcomes Cure rates
Failure rates
Egg counts at baseline, four and six weeks
Notes Location: Gabon
Setting: two ANC health care centres
Endemicity: highly endemic for S. haematobium and malaria
Dates: Sept 2009 to Dec 2011
Funding: European and Developing Countries Clinical Trial Partnership (EDCCTP),
Malaria in Prengnancy consortium, Karl Landsteiner Gesellschaft
Authors’ conclusion: Mefloquine IPTp is effective against S. haematobium in pregnant
women.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomizations list was computer-
generated andprovided by the independent
MIPPAD trial management team
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Basra 2012 GAB (Continued)
Allocation concealment (selection bias) Low risk Trial assignment was concealed via sealed
opaque envelopes which were opened only
after enrolment of a patient by a trial inves-
tigator
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of outcome assessors.
Incomplete outcome data (attrition bias)
All outcomes
High risk High loss to follow-up, unbalanced (in the
intervention group 18/48 = 37.5%, in the
control group 3/48 = 6.25%) reasons partly
stated
Selective reporting (reporting bias) Low risk No evidence of selective outcome report-
ing.
Other bias Low risk No risk of other bias.
Befidi Mengue 1992 CMR
Methods RCT
Diagnostics: urine sample preserved with 5 mg sodium azide, sedimentation for one
hour, examination of sediment, egg count
Follow-up: six months (as only time point)
Participants Male primary school students, aged six to 15 years
Number randomized 653, 436 in groups of interest for this review
Exclusion: heavy S. haematobium infections (> 499 eggs/10 mL)
Inclusion: positive for S. haematobium
Interventions 1. Praziquantel 40 mg/kg single dose
2. Placebo
Outcomes Geometric mean egg counts
Weight
Height
Height for age
Weigth for age
Weight for height
MUAC
Triceps skinfold thickness
Mean muscle mass
Hb (reported in a separate publication BefidiMengue 1993, see reference BefidiMengue
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Befidi Mengue 1992 CMR (Continued)
1992 CMR) with slightly higher numbers of participants: 771 randomized, 518 in
treatment groups of interest of this review)
Notes Location: Cameron, Eastern Province, Bertuoa
Setting: urban (capital city of Eastern province), primary school
Endemicity: polyparasitism is common
Dates: not reported
Funding: USAID Cameroon health constraints to rural production project 1608 - 1408
Authors’ conclusion: only demonstrable effect of a single praziquantel treatment on
MUAC
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned, method not stated.
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The placebo tablets were physically identi-
cal to the praziquantel tablets
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up unclear, as numbers fol-
lowed up not reported
Selective reporting (reporting bias) Low risk No evidence for selective reporting.
Other bias Low risk No evidence for other bias.
Borrmann 2001 GAB
Methods RCT
Diagnostics: two urine samples. filtration of 10mL of urine through polycarbonate filters
(Millipore), staining with Trypan blue
Follow-up at day 56 (as only time point)
Participants School children aged six to 15 years
Participants randomized: 300
Inclusion: S. haematobium positive, asymptomatic S. haematobium infection
Exclusion: symptomatic schistosomiasis, recent schistosomiasis treatment, serious un-
derlying disease, pregnancy or lactation, anaemia (Hb < 7 G/dL)
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Borrmann 2001 GAB (Continued)
Interventions 1. Praziquantel 40 mg/kg single dose
2. Artesunate 4 mg/kg once daily for three days
3. Artesunate 4 mg/kg once daily for three days and praziquantel 40 mg/kg single dose
4. Placebo
Outcomes Cure rates
Failure rates
Egg reduction rates
Microhaematuria
(Adverse events day seven)
Notes Location: Gabon, province Moyen Ogone
Setting: rural villages
Endemicity: high (prevalence 80% in school children)
Dates: Oct. 2000 to Feb 2001
Funding: tablet donation Sanofi (Artesunate), Medochemie (Praziquantel)
Authors’ conclusions: Efficacy of artesunate for S. haematobium treatment as single med-
ication or in combination is low.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomization code was generated by
computer.
Allocation concealment (selection bias) Low risk The trial drugs were prepared in plastic
bags, which were labelled sequentially with
treatment numbers according to the ran-
domization code
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind.
Praziquantel placebo and artesunate
placebo were identical in appearance to the
respective active substance tablets
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low loss to follow-up (7.6%).
Selective reporting (reporting bias) Unclear risk Haemoglobin measurements, proteinuria
and leucocyturia at day 56 not reported
Other bias Low risk No evidence for other bias.
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Davis 1981 ZMB
Methods RCT
Diagnostics: three successive daily schistosome egg countsmade on a random10mLurine
sub sample of the total bladder content by a filtration staining technique; quantitative
hatching technique (enumeration of miracidia, recently dead eggs and black eggs)
Follow-up: three consecutive daily urine samples, quantitative hatching test
Follow-up: at 1, 3, 7, 12 and 24 months
Participants School children aged seven to 17 years
Number followed up after one month 151, number randomized not reported
Inclusion: S. haematobium positive
Exclusion: pregnant or lactating women, no serious acute coexistent diseases or compli-
cations, no other treatment during the past six months, older than six years
Interventions 1. Praziquantel 30 mg/kg single dose
2. Praziquantel 40 mg/kg single dose
3. Praziquantel 20 mg/kg 2 x daily
Outcomes Cure rate
Failure rate
Notes Location: Zambia, Ndola
Setting: eight rural schools
Dates: not reported
Endemicity: high
Funding: Parasitic Disease Programme for Research and Training in Tropical diseases
Authors’ conclusion: treatment groups clinically and statistically comparable
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned, randomnumber table.
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Single blind technique.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low loss to follow-up (3.7% to 6%) at 1,
3 and 7 months.
Selective reporting (reporting bias) Low risk No evidence of selective reporting (some
investigations at baseline not reported)
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Davis 1981 ZMB (Continued)
Other bias Low risk No evidence of other bias.
de Jonge 1990 SDN
Methods RCT
Diagnostics: urine collection after 250 mL soda drink at midday. Trypan blue staining
technique (if the egg concentration was less than 10 eggs per 10 mL urine, the whole
volume (up to 350 mL) was filtered)
Follow-up one and five months
Participants Male primary school children aged six to 11 years
Patients randomized 160, participants randomized into treatment groups of interest for
this review: 107
Inclusion: co-infection with S. haematobium and S. mansoni
Exclusion: not reported
Interventions 1. Praziquantel 40 mg/kg single dose
2. Metrifonate 2 x 10 mg/kg, dose interval 14 weeks
3. Oxaminique 60 mg/kg single dose
4. Multivitamin single dose
Outcomes Failure
Egg count
Notes Location: Sudan Gezira
Setting: rural, village primary schools
Funding: Science and Technology for Development, EC, WHO, UNDP, World bank,
Special Programme for Training & Research. Gesellschaft für technische Zusammenar-
beit
Dates: not reported
Endemicity: high for both S. mansoni and S. haematobium
Authors’ conclusion: discussion of correlation of parasitological outcomes andCAA titres
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly divided”.
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Multivitamin as placebo, but blinding not
mentioned.
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de Jonge 1990 SDN (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
High risk Loss to follow-up high, at one months up
to 23%, at five months up to 28%
Selective reporting (reporting bias) Low risk No evidence for selective reporting.
Other bias Low risk No evidence for other bias.
Inyang Etoh 2009 NGA
Methods RCT
Diagnostics: collection of two urine samples at midday (12.00 to 14.00) after exercise
on two consecutive days, agitation of urine sample, preservation of eggs, staining (1%
aqueous solution, carbol fuchsin), filtration, egg counts
Follow-up at eight weeks (as only time point)
Participants School children aged four to 20 years (nursery school, primary and junior secondary
schools, students)
Number randomized 260 children into five groups
Inclusion: healthy, able to swallow the medication
Exclusion: serious underlying disease, recent treatment for schistosomiasis, > 20 yrs, < 4
yrs old
Interventions 1. Praziquantel 40 mg/kg single dose and placebo
2. Praziquantel 40 mg/kg single dose only
3. Artesunate 4 mg/kg 1 x daily for three days and placebo
4. Artesunate 4 mg/kg 1 x daily for three days only
5. Praziquantel 40 mg/kg single dose and artesunate 4 mg/kg 1 x daily for three days
6. Placebo and placebo
Outcomes Cure
Egg counts and egg reduction rate
Haematuria
Proteinuria
Notes Location: Nigeria, Adim community, Cross RIver State
Setting: school students
Dates: August 2005 to June 2006
Endemicity: seasonal transmission
Funding: partly funded by the management of the University of Calabar
Authors’ conclusion: both praziquantel and artesunate in the stated doses are safe, well-
tolerated and effective in the trial area. Combined treatment is more effective and single
treatment with any of the drugs
Risk of bias
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Inyang Etoh 2009 NGA (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomised”.
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Placebo not identical in appearance.
Blinding not mentioned.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up of 15.4% and 19.2% at
day 56.
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk No evidence of other bias.
Jewsbury 1976 ZWE
Methods RCT
Diagnostics: three urine samples on three consecutive days, determination of egg counts
and cure rates
Follow-up at week 11 and week 36
Participants Children, aged three to 15 years (and older)
Number of children randomized: 179
Number of children analysed 114 (complete case analysis)
Inclusion: S. haematobium positive
Exclusion: not reported
Interventions 1. Metrifonate 7.5 mg x 3, dose interval two weeks
2. Control: no intervention
Outcomes Cure rate
Failure rate
Median urine egg counts
Notes Location: Zimbabwe near Salibury
Setting: rural, four farms
Dates: not reported
Endemicity: high (pre-infection rate with S. haematobium 80%)
Funding: Drug donation by Bayer
Authors’ conclusion:Metrifonate is safe and effective for the treatment of S. haematobium
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Jewsbury 1976 ZWE (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomised”.
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not mentioned.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
High risk Participant numbers not reported at week
11, high loss to follow-up of 46% at week
36
Selective reporting (reporting bias) Unclear risk Data of week 11 not reported.
Other bias High risk Baseline imbalance; for the infected, un-
treated control group, an infection rate of
89.4% is given at baseline
Kardaman 1985 SDN
Methods RCT
Diagnostics: centrifugation, sediment taken for egg counts
Follow-up at five weeks and three months
Participants School children aged seven to 11 years
Number of children included: 237
Inclusion: co-infection S. haematobium and S. mansoni
Exclusion: receiving medication for any other infection, treatment for schistosomiasis
during the preceding 6 months
Interventions 1. Praziquantel 40 mg/kg single dose
2. Praziquantel 2 x 20 mg/kg in one day, dose interval four to six hours
Outcomes Cure
Failure
Adverse events
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Kardaman 1985 SDN (Continued)
Notes Location: Sudan, Galaga Village
Setting: rural, primary schools
Dates: not reported
Endemicity: high (mixed infections common)
Funding: Parasitic disease programme, WHO
Authors’ conclusion: Results of two regimens not significantly different. Treatment for
this setting has to be repeated every six months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned.
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not mentioned.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up at five weeks up to 4.7%,
at three months up to 8.4%
Selective reporting (reporting bias) Low risk No evidence for selective reporting.
Other bias Low risk No evidence for other bias.
Keiser 2010 CIV
Methods RCT
Diagnostics: collection of two urine specimen at midday (10.00 to 14.00), samples were
rigorously shaken, filtration of 10 mL through a 13 mL filter with 25 µm diameter
Follow-up at 26 days
Participants School children aged eight to 12 years
Participants randomized 83
Inclusion: confirmed S. haematobium infection
Exclusion: not reported
Interventions 1. Praziquantel 40 mg/kg single dose
2. Mefloquine 25 mg/kg single dose
3. Artesunate 4 mg/kg 1 x daily for three days
4. Artesunate 3 x 100 mg and mefloquine 250 mg
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Keiser 2010 CIV (Continued)
Outcomes Cure rates
Failure rate
Egg count
Egg reduction rate
Adverse effects
Notes Location: Cote d’ Ivoire, district Agboville
Setting: rural, school children
Dates: November to December 2009
Funding: support Dafra Pharma, Mepha for drug donations
Endemicity: highly endemic, 40% among school children
Authors’ conclusion: High cure rates with praziquantel, promising results for mefloquine
- artesunate (in the standard dose for malaria)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “using a computer generated randomisa-
tion code”. Seven children were added to
one treatment group in a non-randomized
manner
Allocation concealment (selection bias) High risk Not implemented (email correspondence
with author).
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up during the trial (day
26).
Selective reporting (reporting bias) Low risk Urinary findings day 26 not reported (not
available, email correspondence with au-
thor)
Other bias Low risk No evidence of other sources of bias.
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King 1989 KEN
Methods RCT
Diagnostics: collection of midday urine sample (10.00 to 13.00), urine filtration tech-
nique with nucleopore filters, egg count
Follow-up at two to three months
Participants Primary school students aged five to 17 years and adult participants over 20 years
Number of patients randomized 280 (34 adults, 246 children)
Inclusion: egg count > 50 eggs/10 mL urine
Exclusion: not reported
Interventions 1. Praziquantel 10 mg/kg single dose
2. Praziquantel 20 mg/kg single dose
3. Praziquantel 30 mg/kg single dose
4. Praziquantel 40 mg/kg single dose
Outcomes Cure
Egg counts
Severity of infection
Proteinuria
Haematuria
Notes Location: Kenya, Kwale district
Setting: rural, primary schools
Dates: not reported
Endemicity: high
Funding: Edna McConnell Clark Foundation
Authors’ conclusion: low dose (20 mg/kg) is as effective as standard dose (40 mg/kg) of
praziquantel (reductions in parasite burden and morbidity) for population based control
programmes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random allocation, pre-randomized cards.
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Clinicians not blinded to the intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors and laboratory staff
blinded to the intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up at two to three months
9% to 14%, balanced between groups
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King 1989 KEN (Continued)
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk No evidence for other sources of bias.
King 1990 KEN
Methods RCT
Diagnostics: sample collection of midday urine (10.00 to 13.00), nucleopore filtration,
egg counts
Follow-up at one, two and three years
Participants Primary school children aged four to 21 years
Number randomized 1813
Inclusion: S. haematobium positive
Exclusion: not reported
Interventions 1. Praziquantel 40 mg/kg single dose once a year
2. Metrifonate 10 mg/kg single dose three times a year, dose interval four months
Outcomes Haematuria
Proteinuria
Ultrasound (hydronephrosis, bladder thickening, bladder deformity)
Notes Location: Kenya, Coast Province, Kwale Province, Msambweni Area
Setting: rural, primary schools, nine villages
Dates: 1984
Endemicity: high (prevalence in school children 60% to 85%)
Funding: Edna McConnell Clark Foundation, WHO, Rockefeller Foundation
Authors’ conclusion: Both regimens had significant effects on the prevalence of hema-
turia, proteinuria, and bladder abnormalities. no significant differences between the two
drugs. No effect on hydronephrosis at twelve months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random allocation with pre-randomized
cards.
Allocation concealment (selection bias) High risk “Treatment allocation was not concealed
to the investigators” (email correspondence
with author)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants (different taste
and appearance of commercially purchased
drugs) email response)
no blinding of clinicians
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King 1990 KEN (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Evaluators were effectively blinded to the
treatment status of the children they were
testing (email correspondence with author)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear.
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk No evidence of other bias.
King 2002 KEN
Methods RCT
Diagnostics: Collection of two mid-day (10:00 to 14:00) on different days, filtration,
Nucleopore) Intensity of infection assigned according to the highest one day egg count
in the repeated daily testing
Follow-up at six weeks and nine months
Participants School children and adults, aged four to 23 years
Number of participants randomized 291
Inclusion: S. haematobium positive
Exclusion: not reported
Interventions 1. Praziquantel 40 mg/kg single dose
2. Praziquantel 20 mg/kg single dose
Outcomes Cure
Egg count
Ultrasound findings (Hydronephrosis, bladder thickening and bladder irregularity)
Notes Location: Kenya, Coastal Province, Kwale District
Setting: rural, village schools
Dates: 1992 to 1993
Endemicity: high
Funding: WHO, TDR, Rockefeller Foundation Joint Funding Venture and National
Institutes of Health
Authors’ conclusion: Praziquantel 20 mg and praziquantel 40 mg are equally effective
in reducing structural urinary tract morbidity over nine months. A praziquantel dose of
20 mg/kg may be sufficient for practical control of renal and bladder morbidity due to
S. haematobium in certain settings: not reported
(trial might be underpowered for ultrasound findings).
Risk of bias
Bias Authors’ judgement Support for judgement
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King 2002 KEN (Continued)
Random sequence generation (selection
bias)
Low risk “Infected students were then individually
randomised to therapy...by computer ran-
dom number generation.”
Allocation concealment (selection bias) High risk Allocation was not concealed.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of personnel: “Dosing assign-
ment lists were transmitted to clinical staff
responsible for treatment”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of outcome assessors (clinicians,
parasitologists).
“Assignments were masked form staff par-
asitologists and physicians responsible for
follow-up until the end of the study.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Loss to follow-up 31% at six weeks.
Selective reporting (reporting bias) Low risk No evidence of selective outcome report-
ing.
Other bias Low risk Important baseline characteristics (egg
counts) not reported at baseline
McMahon 1979 TZA
Methods RCT
Diagnostics: Collection of three midday (10.00 to 13.00) urine samples on three con-
secutive days, sedimentation in a conical flask for 30 mins, taking of a 10 mL sample
of the bottom of the flask, centrifugation and processing of the deposit 5 mL boiled,
cooled water added to deposit, miracidia hatching test, fixing and staining of miracidia
(alcohol and eosin), microscopy and count
Follow-up at one, three and six months.
Participants School children aged seven to 15 years
No. of children randomized: 138
Inclusion: S. haematobium positive
Exclusion: not reported
Interventions 1. Praziquantel 30 mg/kg single dose
2. Praziquantel 40 mg/kg single dose
3. Praziquantel 2 x 20 mg in one day, dose interval four hours
4. Placebo
Outcomes Cure
Egg counts
Adverse effects
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McMahon 1979 TZA (Continued)
Notes Location: Tanzania, Tanga region
Setting: school, rural area
Endemicity: high, transmission may vary greatly form year to year and season to season
Dates: not reported
Funding: MRC/WHO/Tanzania Helminthiasis Research Unit, Tanga
Authors’ conclusion: Praziquantel in the given doses is not toxic. Praziquantel 40 mg did
not affect the therapeutic response in children with large egg loads
As cure rates are influenced by pre-treatment egg loads, trials of higher doses in patients
with high egg loads needed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly sub-divided into four groups ac-
cording to previously arranged blocks
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not mentioned.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up 10% to 15% at 1, 3 and
6 months.
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk Baseline characteristics not reported.
McMahon 1983 TZA
Methods RCT
Diagnostics: collection of two midday (10.00 to 14.00) samples on two consecutive days
for initial diagnosis, of three samples for follow-up), quantitative hatching technique,
sedimentation of 10 mL urine
Follow-up at two and four months
Participants School children and adults
Number of participants randomized: 90
Inclusion: 250 miracidia/10 mL urine
Exclusion: not reported
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McMahon 1983 TZA (Continued)
Interventions 1. Praziquantel 30 mg/kg single dose
2. Metrifonate 10 mg/kg 1 x daily, dose interval 14 days
3. Niridazole 25 mg/kg 1 x daily for six days, dose interval one day
Outcomes Cure rates
Egg reduction rates
Adverse effects
Notes Location: Tanzania, Tanga region
Setting: not stated
Endemicity: high
Dates: not reported
Funding: MRC/WHO/Tazania Helminthiasis Research unit, Tanga, Biltricide (Praz-
iqantel) was supplied by Bayer
Authors conclusion: Praziquantel was more effective than metrifonate and niridazole.
Side effects were minor
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly allocated.
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not mentioned; use of different regimens,
no use of placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
High risk Loss to follow-up partly high, not balanced
(at four months 0% in the praziquantel
group, 26% in the metrifonate and 30% in
the niridazole group
Selective reporting (reporting bias) Unclear risk No evidence of selective reporting.
Other bias Low risk Few baseline characteristics reported.
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Mott 1985 GHA
Methods RCT
Diagnostics: collection or one urine sample, two random samples out of this urine sample
were processed. quantitative urine filtration technique
Follow-up at three and six months
Participants Residents “entire population of five settlements”, aged six years or older
Number of people randomized 266
Inclusion: S. haematobium infected
Exclusion: pregnancy, alcoholism, severe debilitating disease
Interventions 1. Praziquantel 30 mg/kg single dose
2. Praziquantel 40 mg/kg single dose
Outcomes Cure rate
Egg count, egg reduction rate
(Urinary results not reported by treatment group)
Notes Location: Ghana, Lake Volta
Setting: rural, five settlements
Dates: not reported
Endemicity: not reported
Funding: Parasitic Diseases Programme WHO/UNDP/Wold bank/ WHO Special Pro-
gramme for Research and Training in Tropical diseases
Authors’ conclusions: Similar efficacy of Praziquantel 30 mg and 40 mg in this trial.
Praziquantel reduces clinical signs (macrohaematuria) and morbidity in urinary schisto-
somiasis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned.
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not mentioned.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up at six months 11.6%.
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
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Mott 1985 GHA (Continued)
Other bias Low risk Baseline characteristics not reported per
group.
Olds 1999 KEN
Methods RCT
Diagnostics: Eggs from 2 x 10 mL samples were filtered on membranes (Nucleopore)
Follow at 45 days, 90 days, six months and one year
Participants School children aged four to 18 years
Number of participants pos for S. haematobium: 380
Inclusion: S. haematobium positive
Exclusion: pregnancy or marriage, failure to submit two stool specimens prior to initial
therapy, known allergy to praziquantel or albendazole, treatment within the past six
months
Interventions 1. Praziquantel 40 mg/kg single dose and albendazole 400 mg single dose
2. Praziquantel 40 mg/kg single dose and placebo
3. Albendazole 400 mg single dose and placebo
4. Placebo and placebo
Outcomes Cure
Egg count
Ultrasound
Weight, height, skinfold thickness, MUAC
Hb
Adverse effects
Notes Location: Kenya, Kwale District, Coast province for S. haematobium (multi centre trial
for different Schistosoma species, conducted in different countries)
Setting: rural
Endemicity: endemic ascariasis, hookworm, trichuris, S. haematobium
Dates: not reported
Funding: WHO/TDR Tropical disease research
Authors’ conclusion: Combined mass treatment of children with albendazole and praz-
iquantel produced not more side effects than treatment with praziquantel alone
Combined mass treatment should have an important impact on schistosoma and hook-
worm prevalence and intensity and improves Hb levels
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomized in one of four treatment
groups, block design with block size of 80
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Olds 1999 KEN (Continued)
Allocation concealment (selection bias) Low risk Randomization lists were prepared by
WHO/TDR using a randomized block de-
sign
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind, placebo controlled; physi-
cally identical placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up10%at sixmonths, loss to
follow-up 17% at one year (for all groups)
Selective reporting (reporting bias) High risk Hb values, proteinuria, hematuria, ultra-
sound findings not reported
Other bias Low risk No evidence for other bias.
Omer 1981 SDN
Methods RCT
Diagnosis: sedimentation concentration technique, miracidial hatching
Follow-up at seven days, one month, three to four months, six months
Participants Patients presenting to theHospital of Tropical diseases, Karthoum, aged eight to 16 years
Number of patients randomized: 152
Inclusion: mixed S. haematobium and S. mansoni infections
Exclusion: under eight years of age, advanced stage of disease, severe anaemia, poor
general health
Interventions 1. Praziquantel 30 mg/kg single dose
2. Praziquantel 40 mg/kg single dose
3. Praziquantel 2 x 20 mg/kg within one day
Outcomes Cure rates
Egg counts
Adverse events
Laboratory parameters at day 0 or 1 and at day 1 or 2, not of interest for this review
Notes Location: Sudan, Karthoum
Setting: Hospital of Tropical Diseases, Karthoum
Endemicity: not reported
Dates: 1978 to 1979
Funding: not reported
Authors’ conclusion: Praziquantel is easily applicable, safe and effective in the treatment
of mixed (S. haematobium and S. mansoni) infections
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Omer 1981 SDN (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomized.
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Single blind.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up at six months 17% to
22%, balanced.
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk No evidence of other bias.
Oyediran 1981 NGA
Methods RCT
Diagnostics: collection of a midday urine sample (12.00 to 2.00), taking a 10 mL sub
sample, filtration of the urine, staining with Ninhydrin, counting of the eggs retained
on the filter paper
Follow-up at one, three and six months
Participants Primary school children aged nine to 16 years
Participants randomized: 90
Inclusion criteria: mean egg count 80 eggs/10 mL, viable eggs, aged over six years
Exclusion criteria: under six years, concurrent acute or serious illness, antischistosomal
treatment within the past six months
Interventions Praziquantel 30 mg/kg single dose
Praziquantel 40 mg/kg single dose
Praziquantel 2 x 20 mg/kg, dose interval three to four hours
Placebo
Outcomes Egg counts
Notes Nigeria, Oyo State
Setting: Primary Schools
Dates: not reported
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Oyediran 1981 NGA (Continued)
Funding: not reported
Authors’ conclusion: No significant difference in efficacy between the three dosage regi-
mens, trials on the effects of lower doses required
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers.
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Placebo single dose
The treatment group received a split dose
of praziquantel, blinding not mentioned
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
High risk High loss to follow-up, not balanced (at
one month 4 to 17%, at three months 17
to 23%, at six month 26 to38%, at twelve
months 76% to 87%)
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk No evidence of other bias.
Pugh 1983 MWI
Methods RCT
Diagnostics: collection of two midday urine samples on two consecutive days filtration,
staining and egg count
Follow-up at one, three and six months. Further follow-up reported at nine, 12, 15 and
24 months in a separate publication (Pugh 1983 MWI)
Participants School children aged five to 18 years
Number of participants randomized: 499
Inclusion: mean egg count (S. haematobium) > 19/10 mL
Exclusion: malaise, febrile illness, treatment with schistosomacidal drugs in the past six
months
Interventions 1. Praziquantel 40 mg/kg single dose
2. Niridazole 25 mg/kg single dose and metrifonate 10 mg/kg single dose
3. Metrifonate 10 mg/kg single dose
4. Niridazole 25 mg/kg single dose
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Pugh 1983 MWI (Continued)
5. Placebo
Outcomes Cure
Geometric mean egg counts
Egg reduction rates
Notes Location: Malawi, Pirimiti Area, Phalombe plain
Setting: rural
Endemicity: seasonal
Funding: Overseas Development Administration, U.K. MoH Malawi. Praziquatel sup-
plied by Bayer
Authors’ conclusion: Praziquantel is superior to the other drugs studied in this trial, it
is the most efficient and convenient drug available. Maintained low egg output at 24
months was presumably influenced by low levels of transmission during the second year
of the trial, which was very dry
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Use of a randomized x-y list.
Allocation concealment (selection bias) Low risk ”An independent worker had sole and con-
fidential access to a randomised x-y list.“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double blind.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up low at one months: 0%
to 4.1%, at three months 8% to 11% in
treatment groups, up to 23% in the placebo
group; at six months 20% in the treat-
ment group. Loss to follow-up high at 24
months, about 40% to 70 %
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias High risk Baseline imbalance in terms of intensity of
infection.
”In accordance to with local ethical guide-
lines the placebo group consisted only of
children with light (20-124 ova/10mL or
moderate (125 to 4999 ova/10 mL) infec-
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Pugh 1983 MWI (Continued)
tions before treatment. Important baseline
characteristics not reported (age, weight)
Rey 1983 NER
Methods RCT
Diagnostics: collection of two urine samples, filtration (Swinex 13 Filter Millipore, 13
mm diameter), fixation and staining (Lugol), egg counts
Length of follow-up: one, three and six months
Participants Participants: recruits aged 18 to 20 years and college students aged 15 to 19 years
Number of participants randomized: 207
(co-infection with S. mansoni likely, but not investigated)
Inclusion: S. haematobium positive
Exclusion: not reported
Interventions 1. Praziquantel 30 mg/kg daily dose
2. Praziquantel 40 mg/kg daily dose
3. Oltipraz 17.5 mg/kg 2 x daily in one day
Outcomes Failure
Egg reduction rates
Notes Location: Niger
Setting: not reported
Endemicity: not reported
Dates: not reported
Funding: not reported
Authors’ conclusion: No significant difference found between praziquantel 30 mg/kg
and praziquantel 40 mg/kg
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomized, tirage au sort.
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not mentioned, no use of placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned.
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Rey 1983 NER (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up acceptable at one month
(9%to15%) and threemonths 9%to11%,
high at six months (39% to 47%)
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk Baseline characteristics not reported.
Rey 1984 NER
Methods RCT
Diagnostics: urine filtration, normal filtration paper, egg counts (no further details given)
Follow-up for children (aged five to 15 years) at 1, 5 and 6 months, for adults (> 15
years) at six months only
Participants Children older than five years and adults
Participants treated and controlled: 268 randomized, 143 participants at one month,
randomized
Inclusion: not reported
Exclusion: not reported
Interventions 1. Metrifonate 10 mg/kg single dose
2. Metrifonate 10 mg/kg two doses with a dose interval of two weeks
3. Metrifonate 10 mg/kg three doses with a dose interval of two weeks
Outcomes Cure rate
Egg reduction
Notes Location: Niger, near Niamey
Setting: not reported
Endemicity: high, the trial was conducted in the season of low transmission
Dates: not reported
Funding: not reported
Authors’ conclusions: Recommendation against the combined metrifonate niridazole
treatment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “au hasard ”, random number table.
Allocation concealment (selection bias) Unclear risk No comment.
Blinding of participants and personnel
(performance bias)
Unclear risk No comment.
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Rey 1984 NER (Continued)
All outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No comment.
Incomplete outcome data (attrition bias)
All outcomes
High risk Loss to follow-up high: at one month 50%,
at four months 39%
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk No evidence of other bias, funding not
stated.
Sacko 2009 MLI
Methods RCT
Diagnostics: Collection of three urine samples between 10 am and 2 PM on three
consecutive days. 10 mL of urine passed through a nucleopore filter, Swinnex filter
support. Egg counts
Follow-up at 3, 6 and 18 months
Participants School children aged seven to 14 years
Number of participants randomized: 603
Inclusion: not reported
Exclusion: not reported
Interventions Praziquantel 40 mg/kg single dose
Praziquantel 40 mg/kg two doses, interval two weeks
Outcomes Cure rate
Egg reduction
Haematuria
Notes Location: Mali, Niger River Basin
Setting: rural, primary schools
Endemicity: not reported
Dates: not reported
Funding: not reported
Authors’ conclusion: Significantly reduced prevalence of microhematuria with prazi-
quantel x 2, this could indicate reduction of morbidity
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomized (SPSS generated random
number tables).
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Sacko 2009 MLI (Continued)
Allocation concealment (selection bias) Low risk Not mentioned.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind, placebo-controlled.
Placebo tablets were of the same form and
colour as praziquantel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up unclear, as number ran-
domized were not reported, only the num-
bers at first follow-up at three months
Selective reporting (reporting bias) Low risk Follow-up data at six and 18 months re-
ported in graphs, not in numbers
Other bias Low risk No evidence for other bias.
Stephenson 1985 KEN
Methods RCT
Diagnostics: nucleopore filter method of Peters and others
collection of a midday urine sample (complete bladder content, 11.00 to 12.00) after
200 mL of fruit drink, nucleopore filter method of Peters and others, staining with 0.5
trypan blue, egg counts in 10 mL of urine adjusted for the total volume of each urine
specimen
Follow-up for six months
Participants Primary school children aged six to 16 years
Number of participants randomized: 400
Inclusion: light to moderate S. haematobium infections at exam 1
Exclusion: not reported
Interventions 1. Metrifonate 7.5 mg/kg three doses, dose interval one to two weeks
2. Placebo: gelatin capsules
Outcomes Parasitological failure and cure
Egg counts
Egg reduction rate
Haemoglobin
Anthropometric measures weight, height, weight for height, middle upper arm circum-
ference, triceps and subscapular skinfold thickness
Liver size
Spleen size
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Stephenson 1985 KEN (Continued)
Notes Location: Kenya, Kwale District, Coast Province
Setting: rural, four primary schools
Endemicity: highly endemic
Dates: not reported
Funding: not reported
Authors’ conclusion: S. haematobium infections can precipitate or aggravate anaemia in
vulnerable children (poor iron intake, high endemicity of other parasites). S. haemato-
bium treatment improves Hb levels.
S. haematobium treatment may improve child growth (in populations were hookworm
infections and Protein EnergyMalnutrition is common). S. haematobium treatment may
be associated with regression of splenomegaly and hepatomegaly in children treated for
S. haematobium infection. Population-based treatment is recommended.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Allocated at random.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Use of placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Examinations 1 and 2 were carried out in a
blind fashion with the same team of work-
ers
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up unclear, as results were
reported as proportions
Selective reporting (reporting bias) Low risk No evidence of selective outcome report-
ing.
Other bias Low risk No evidence of other sources of bias.
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Stephenson 1989 KEN
Methods RCT
Diagnostics: collection of amidday urine sample (complete bladder content, 11.00 to 12.
00) after 200 mL of fruit drink, nucleotome filter method of Peters and others, staining
with 0.5 trypan blue, egg counts in 10 mL of urine adjusted for the total volume of each
urine specimen
Follow-up at eight months (as only time point)
Latham 1990, a sub-study nested within Stephenson 1989 KEN, followed up patients
at five weeks (as only time point)
Participants Primary school children, 98% Muslim of the Wadigo tribe, aged eight to 13 years
Number of participants randomized: not reported
Number of participants analysed: 312
Inclusion: light to moderate infections
Exclusion: anaemia (Hb < 8 G/dL, severe infections)
Latham 1990 included 48 boys aged seven to 15 years with no sign of puberty, high egg
counts, Hb > 8 G/dL, cooperation for physical fitness test
Interventions 1. Praziquantel 40 mg/kg single dose
2. Metrifonate 10 mg/kg single dose
3. Placebo
As a nested study, Latham had the same study arms.
Outcomes Parasitological failure
Egg counts (geometric and arithmetic)
Anthropometric measurements: weight, height, MUAC, triceps skinfold thickness, sub-
scapular skinfold thickness,
Haemoglobin
Liver size
Spleen size
Latham 1990 (reference see Stephenson 1989 KEN) reports parasitological failure, egg
reduction rate and anthropometric measures: weight, height, skinfold thickness, MUAC
at five weeks at five weeks, and additionally reports on
Physical fitness: Harvard Step test,
Appetite (quantity of porridge consumed)
Questionnaire of clinical symptoms
Notes Location: Kenya, Kwale district, Coast Province
Setting: rural, primary schools
Endemicity: endemic for S. haematobium, hookworm and malaria
Dates: March 1986 to April 1986
Funding: Edna McConnell Clark Foundation, grant 284-0120
Authors’ conclusion: Both metrifonate and praziquantel are effective in reducing egg
excretion and are both recommended for population based treatment. Praziquantel is
more effective. S. haematobium treatment with a single dose of either metrifonate or
praziquantel may improve child growth in areas were hookworms and malnutrition are
common and appears to have a beneficial effect on hepatomegaly and splenomegaly
Treatment of moderate to heavy S. haematobium infections with metrifonate or praz-
iquantel in undernourished schoolboys can improve physical fitness, growth rates and
appetite within approximately one month
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Stephenson 1989 KEN (Continued)
Recommendation for widespread population based chemotherapy in highly endemic
areas as Kwale district
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Allocated at random.
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Use of placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Examinations carried out in a blind fash-
ion.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up 10%, 3 participants not
accounted for.
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk No evidence for other source of bias.
Taylor 1988 ZWE
Methods RCT
Diagnostics: urine sample collection; three midday urine samples (10.00 to 14.00),
filtration (13 mm nytrl filter), staining with Lugol
Follow-up at 1, 3 and 6 months
Participants School children aged ten to 15 years,mixed infectionwith S. haematobium and S.mansoni
Number of participants randomized: 373
Inclusion: mixed S. haematobium and S. mansoni infection
Exclusion: not reported
Interventions 1. Praziquantel 10 mg/kg single dose
2. Praziquantel 20 mg/kg single dose
3. Praziquantel 30 mg/kg single dose
4. Praziquantel 40 mg/kg single dose
4. Control: Nil
Outcomes Parasitological cure
Egg count
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Taylor 1988 ZWE (Continued)
Notes Location: Zimbabwe
Setting rural, primary school
Endemicity: seasonal transmission
Date: not reported
Funding: Rockefeller Foundation (financial support)
Authors’ conclusion: Doses of 20 to 40 mg praziquantel may be equally effective in S.
haematobium infection
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned.
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Single blind manner “only the principal in-
vestigator knew which children had been
assigned to which treatment group.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up unclear, as only means
and percentages of cure are reported
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk No evidence for other source of bias.
Tchuente 2004 CMR
Methods RCT
Diagnostics: collection of two urine samples on two consecutive days in 50 mL plastic
screw cap vials, processing in field laboratory, agitation of urine (from dispersal of eggs)
filtration of 10 mL (Nucleopore filter), egg counts
Length of follow-up 3, 6 and 9 weeks
Participants School children, age not reported
Number of participants randomized: 592
Inclusion: S. haematobium positive
Exclusion: not reported
Interventions 1. Praziquantel 40 mg/kg single dose
2. Praziquantel 40 mg/kg two single doses, dose interval three weeks
3. Praziquantel 40 mg/kg three single doses, dose interval three weeks
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Tchuente 2004 CMR (Continued)
Outcomes Cure rates
Egg counts, egg reduction rates
Proteinuria
Notes Location: Cameroon, Loum
Setting: urban, schools
Date: April to June 2002
Endemicity: endemic all year, prevalence amongst school children 41.8%, trial carried
out during high transmission period
Funding: European Commission INCO-DC (ICA-4-CT-2001-10079)
Authors’ conclusion: No significant differences between the three dosing regimens, per-
sistent high cure rates with a single dose of Praziquantel. Findings suggest efficacy of
praziquantel against immature schistosoma stages
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Assigned to random groups.
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No use of placebo mentioned.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
High risk High loss to follow-up of 13% at six weeks,
very high loss to follow-up of 58.6%at nine
weeks (change in schools schedules)
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk No evidence of other bias.
van den Biggelaar 02 GAB
Methods RCT
Diagnostics: collection of urine samples on three different days, filtration of 10mL urine,
nucleopore pore size 13 µm), staining with ninhydrin, eggs count
Follow-up at two and three years, length of follow-up three years
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van den Biggelaar 02 GAB (Continued)
Participants School children aged five to 14 years
Participants randomized: 135
Inclusion: positive for S. haematobium eggs
Exclusion: not reported
Interventions Praziquantel 40 mg/kg single dose
Praziquantel 40 mg/kg in repeated doses, dose interval three months, over two years
Outcomes Cure rates, failure rates
Egg counts
Microhaematuria
Notes Location: Gaboon, near Lambarene
Setting: rural, village schools
Endemicity: high
Funding: not reported
Dates: not reported
Authors’ conclusion: relate to immunologic outcomes also measured by this trial, but
not of interest for this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Allocated randomly.
Allocation concealment (selection bias) High risk “The allocationof children to the treatment
group was open.”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Use of placebo (given every three months)
not mentioned.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
High risk High loss to follow-up (not balanced, rea-
sons not given):
at 24 months 8%, 23%, 44% in different
treatment groups;
at 36 months 40%, 64%, 77%.
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk No evidence of other bias.
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Wilkins 1987 GMB
Methods RCT
Diagnostics:
Follow-up at two to three months
Participants Residents aged two to 19 years, median age 9.5 years
Participants randomized: not reported
Interventions 1. Praziquantel 10 mg/kg
2. Praziquantel 20 mg/kg
3. Praziquantel 40 mg/kg
4. Metrifonate 10 mg/kg
5. Praziquantel 10 mg/kg and metrifonate 10 mg/kg
Outcomes Egg counts
Side effects
Notes Location: Gambia Upper River Division, Nyanamari
Setting: rural
Endemicity: seasonal, trial conducted during season of low transmission
Dates: not reported
Funding: not reported
Authors’ conclusion: Mass treatment of intensely infected groups should be based on the
standard dose of praziquantel, with metrifonate as second choice
Note: only one of the two trials reported in this publication, theNyanamari trial, fulfilled
the inclusion criteria
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Subjects...were stratified into four age
groups and within each age stratum were
ordered by intensity of egg counts. They
were then placed sequentially into groups
of five. Computer generated random sets
of the numbers one to five were used to al-
located on subject in each group of five to
each of the five regimens used.”
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Placebo and blinding not mentioned.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned.
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Wilkins 1987 GMB (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up unclear, as cure rates are
reported as percentages
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk Baseline characteristics not reported.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aryeetey 1999 Study of health education and community participation.
Ayoya 2007 No comparison group (treatment groups receive praziquantel with or without iron supplements and
multivitamins)
Bausch 1995 Not a RCT.
Beasley 1999 This study compares a combination of praziquantel and albendazole with placebo. This outcome is not
of interest for this review
Bejon 2008 Study of gastrointestinal helminths, not urinary schistosomiasis
Bhargava 2003 This study does not report baseline criteria for control group, as the control group was not screened at
baseline
Boulanger 2007 No comparison group (both groups receive artesunate).
Burchard 1984 This study compares praziquantel 2 x 30 mg/kg to oltipraz, which is obsolete. Details of this trial can
be seen in earlier versions of this review
Clarke 1969 Not a RCT.
Clarke 1973 Not a RCT, allotted to groups, “for practical reasons, the infected children in the two senior grades were
set aside for treatment with i.m. hycanthone”
Creasey 1986 This study compares different doses of praziquantel (8 mg/kg, 15 mg/kg and 20 mg/kg) combined
with oxaminique in patients with S. haematobium and S. mansoni co-infections. A comparison of the
praziquantel dosages used is not of interest for this review
Danso-Appiah 2009 Systematic review.
Davis 1966 This study evaluates different doses of ambilhar which is now obsolete. Details of this trial can be seen
in earlier versions of this review
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Davis 1979 Outcomes are not reported per treatment group, only for the total number of participants randomized
De Clercq 2002 Not a RCT, “systematically allocated”.
Druilhe 1981 Not a RCT.
el Hawey 1990 No comparison group.
el Tayeb 1988 This study compares praziquantel 2 x 20 mg/kg to oltipraz 2 x 15 mg/kg, which is now obsolete. Details
of this trial can be seen in earlier versions of this review
el-Zayadi 1985 No outcome of interest reported.
Erikstrup 2008 This is a study of HIV and S. haematobium or S. mansoni co-infection, no outcomes of interest for this
review are reported
Fontanilles 1964 Conference speech.
Forsyth 1964 Not a RCT. “At three of the schools, every sixth injected child received ”curative“ treatment...”
Garba 2001 Study of health education.
Garba 2004 This study evaluates mass treatment with praziquantel without comparison group
Hammad 1997 This cross-sectional study evaluates the diagnosis of urinary schistosomiasis by reagent strip and para-
sitological methods
Jewsbury 1977 No comparison group (sequence of treatment, then prophylaxis within one group)
Jinabhai 2001 This study compares a combination of praziquantel and albendazole with placebo. This outcome is not
of interest for this review
Jordan 1966 Quasi-RCT. “children were allocated to Groups 1-4 corresponding to different regimens of treatment,
in rotation down the list (pre-treatment results in descending order), thus ensuring four groups matched
for egg output.”
Kardaman 1983 No comparison group.
Kern 1984 Study of intestinal manifestations of schistosomiasis, very low number for S. haematobium positive
patients, outcome data not reported separately.
King 1989 Review article.
King 1992 Data reported in other publications.
Kurz 1986 This study evaluates metrifonate in hookworm infections.
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Latham 1983 No comparison group.
Lucas 1969 This study reports ultrasound findings in patients with urinary schistosomiasis after treatment with
Niridazole to a untreated control. Niridazole is now obsolete
Mwanakasale 2009 Study of iron supplementation in S. haematobium treatment with no outcomes of interest for this review.
N’Goran 2003 Study of S. haematobium prevention.
Nagaty 1962 This trial studies the therapy of drug side effects in urinary schistosomiasis treatment
Odongo-Aginya 1996 Not a RCT, study of S. mansoni.
Olsen 2007 Review article.
Pitchford 1978 No comparison group.
Podgore 1994 Study of S. haematobium prevention.
Rabarijaona 2001 Epidemiological survey.
Rey 1984 This study compares oltipraz 30 mg/kg to a combination of metrifonate 10 mg/kg and niridazole 25
mg/kg. Niridazole and oltipraz are now obsolete
Rugemalila 1984 Study of S. mansoni.
Schutte 1983 No comparison group.
Sellin 1986 This study compares metrifonate 10 mg/kg to oltipraz 30 mg/kg, which is now obsolete
Sissoko 2009 MLI This study compared praziquantel to a combination of artesunate with sulfamethoxypyrazine
pyrimethamine; it is therefore not possible to attribute observed effects to artesunate alone
Snyman 1997 Study of calcitriol as experimental antischistosomal treatment
Snyman 1998 Study of levimasole as experimental antischistosomal treatment
Squires 2000 Review article.
Stephenson 1985 No comparison group (compares children of moderate and severe infection intensity with uninfected
children, using the same treatment regimen for infected children)
Taylor 2001 This study compares a combination of praziquantel and albendazole with placebo. This outcome is not
of interest for this review, whereas a comparison the combination of praziquantel and albendazole versus
praziquantel would be of interest
Teesdale 1980 Not a RCT.
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Thigpen 2011 Not a RCT.
Urbani 1997 Epidemiological survey.
Utzinger 2001 Review article.
van Lieshout 1994 Study of S. mansoni.
Wilkins 1987 Simoto trial Not a RCT, alternate allocation.
Wolfe 1967 Not a RCT.
Xiao 2002 Review article.
Zwingenberger 1990 Case study.
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D A T A A N D A N A L Y S E S
Comparison 1. Praziquantel 40 mg/kg single dose versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure 8 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 at one month to two
months
7 864 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.29, 0.59]
1.2 at three months 3 354 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.34, 0.77]
1.3 at five months 1 54 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.58, 0.91]
1.4 at six months 3 332 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.10, 1.84]
1.5 at eight months 1 209 Risk Ratio (M-H, Random, 95% CI) 0.14 [0.08, 0.22]
2 Haematuria at eight weeks 1 119 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.33, 0.84]
3 Haemoglobin 2 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 at baseline 2 727 Mean Difference (IV, Random, 95% CI) -0.17 [-0.35, 0.02]
3.2 at six to eight months 2 727 Mean Difference (IV, Random, 95% CI) -0.08 [-0.24, 0.09]
4 Adverse events 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Diarrhoea 1 156 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Vomiting 2 226 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.15, 2.87]
4.3 Dizziness 2 226 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.11, 1.27]
4.4 Anorexia 1 70 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.05, 0.85]
4.5 Abdominal pain 2 226 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.22, 1.14]
4.6 Tiredness 1 70 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.14, 1.71]
4.7 Weakness 1 70 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.36, 2.57]
4.8 Headache 2 226 Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.02, 1.47]
4.9 Fever 2 226 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.07, 17.22]
4.10 Pain in limbs 1 70 Risk Ratio (M-H, Fixed, 95% CI) 5.59 [0.28, 112.34]
4.11 Itching 1 156 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.19, 5.28]
4.12 Cough 1 156 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.09, 10.78]
4.13 Chills 1 156 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.16, 14.07]
4.14 Nausea 1 156 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.09, 10.78]
4.15 Constipation 1 156 Risk Ratio (M-H, Fixed, 95% CI) 1.51 [0.06, 36.54]
Comparison 2. Praziquantel 40 mg/kg single dose versus lower doses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure at four to
six weeks
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 versus 30 mg/kg 4 401 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.59, 0.99]
1.2 versus 20 mg/kg 2 338 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.59, 0.93]
1.3 versus 10 mg/kg 1 150 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.53, 0.84]
2 Parasitological failure at two to
three months
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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2.1 versus 30 mg/kg 5 517 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.72, 1.24]
2.2 versus 20 mg/kg 3 330 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.56, 0.92]
2.3 versus 10 mg/kg 3 339 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.39, 0.60]
3 Parasitological failure at six to
seven months
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 versus 30 mg/kg 6 669 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.76, 1.23]
3.2 versus 20 mg/kg 1 138 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.53, 1.44]
3.3 versus 10 mg/kg 1 150 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.29, 0.64]
4 Haematuria at three months 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 versus 30 mg/kg 1 117 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.47, 1.67]
4.2 versus 20 mg/kg 1 122 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.60, 2.33]
4.3 versus 10 mg/kg 1 119 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.21, 0.58]
5 Proteinuria at three months 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 versus 30 mg/kg 1 117 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.34, 2.12]
5.2 versus 20 mg/kg 1 122 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.36, 2.30]
5.3 versus 10 mg/kg 1 119 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.12, 0.51]
6 Haematuria at six weeks 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 versus 20 mg/kg 1 245 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.47, 0.86]
7 Proteinuria at six weeks 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 versus 20 mg/kg 1 245 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.46, 0.96]
8 Haematuria at nine months 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 versus 20 mg/kg 1 215 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.44, 0.78]
9 Proteinuria at nine months 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 versus 20 mg/kg 1 214 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.50, 0.90]
10 Adverse events 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 Vomiting 2 163 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.05, 13.51]
10.2 Dizziness 2 163 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.11, 4.62]
10.3 Anorexia 1 65 Risk Ratio (M-H, Random, 95% CI) 4.85 [0.24, 97.31]
10.4 Abdominal pain 2 163 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.23, 5.56]
10.5 Tiredness 1 65 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.10, 1.09]
10.6 Weakness 1 65 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.39, 3.44]
10.7 Headache 2 163 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.08, 2.85]
10.8 Fever 1 65 Risk Ratio (M-H, Random, 95% CI) 2.91 [0.12, 68.95]
10.9 Pain in limbs 1 65 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.08, 1.86]
Comparison 3. Praziquantel 40 mg/kg single dose versus 2 x 20 mg/kg split dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 at one month 3 374 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.51, 1.11]
1.2 at three months 3 361 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.45, 1.20]
1.3 at six to seven months 3 234 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.51, 1.35]
2 Adverse events 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Blood in stool 1 215 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Vomiting 3 373 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.29, 0.86]
2.3 Dizziness 3 373 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.16, 0.94]
2.4 Anorexia 1 69 Risk Ratio (M-H, Fixed, 95% CI) 2.18 [0.21, 22.96]
2.5 Abdominal pain 3 373 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.83, 1.25]
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2.6 Tiredness 1 69 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.12, 1.41]
2.7 Weakness 1 69 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.35, 2.50]
2.8 Headache 2 158 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.20, 1.33]
2.9 Fever 2 284 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.23, 1.23]
2.10 Pain in limbs 1 69 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.09, 2.10]
2.11 Diarrhoea 1 215 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.67, 1.73]
2.12 Skin reaction 1 215 Risk Ratio (M-H, Fixed, 95% CI) 1.84 [0.34, 9.83]
Comparison 4. Praziquantel 40 mg/kg single dose versus praziquantel 2 x 40 mg/kg or 3 x 40 mg/kg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Praziquantel 40 mg/single dose
versus praziquantel 2 x 40 mg/
kg: parasitological failure
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 at six weeks 1 269 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.50, 1.34]
1.2 at nine weeks to three
months
2 686 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.91, 1.25]
1.3 at six months 1 556 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.95, 1.31]
2 Praziquantel 40 mg/kg single
dose versus praziquantel 3 x 40
mg/kg: parasitological failure
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 at nine weeks 1 185 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.42, 2.12]
3 Praziquantel 40 mg/single dose
versus praziquantel 2 x 40 mg/
kg: microhaematuria at six
months
1 300 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.88, 1.56]
Comparison 5. Praziquantel 40 mg/kg single dose versus multiple doses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 at two years 1 62 Risk Ratio (M-H, Fixed, 95% CI) 2.71 [1.47, 5.00]
1.2 at three years 1 43 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.59, 1.42]
2 Haematuria 1 43 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.42, 1.17]
80Drugs for treating urinary schistosomiasis (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Comparison 6. Metrifonate single dose (10 mg/kg) versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 at one month 1 142 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.74, 0.94]
1.2 at two and a half to three
months
1 122 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.85, 0.99]
1.3 at six months 1 102 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.87, 1.02]
1.4 at eight months 1 210 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.54, 0.73]
2 Haemoglobin 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 at baseline 1 207 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.33, 0.33]
2.2 at eight months 1 207 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.05, 0.65]
Comparison 7. Metrifonate multiple doses versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 at one month 1 50 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.65, 1.09]
1.2 at 11 weeks 1 93 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.30, 0.56]
1.3 at five months 1 51 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.76, 1.03]
1.4 at six months 1 400 Risk Ratio (M-H, Random, 95% CI) 0.30 [0.24, 0.37]
2 Haemoglobin 1 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 at baseline 1 400 Mean Difference (IV, Random, 95% CI) -0.17 [-0.45, 0.11]
2.2 at six months 1 391 Mean Difference (IV, Random, 95% CI) 0.30 [0.14, 0.46]
Comparison 8. Metrifonate multiple doses versus single dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure at one
month
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 20 mg/kg versus 10 mg/kg 1 112 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.50, 1.13]
1.2 30 mg/kg versus 10 mg/kg 1 93 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.17, 0.77]
2 Parasitological failure at four
months
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 20 mg/kg versus 10 mg/kg 1 133 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.58, 1.06]
2.2 30 mg/kg versus 10 mg/kg 1 111 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.45, 0.99]
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Comparison 9. Metrifonate 3 doses 2 weeks apart: 7.5 mg/kg versus 5 mg/kg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 at one month 1 201 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.69, 1.21]
1.2 at two months 1 165 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.72, 1.30]
1.3 at three months 1 133 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.67, 1.26]
1.4 at six months 1 139 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [0.99, 2.05]
2 Adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Nausea 1 201 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.05, 5.48]
2.2 Vomiting 1 201 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.06, 15.93]
2.3 Dizziness 1 201 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.06, 15.93]
2.4 Abdominal pain 1 201 Risk Ratio (M-H, Fixed, 95% CI) 3.03 [0.32, 28.64]
2.5 Headache 1 201 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.04, 3.18]
2.6 Heaviness of the tongue 1 201 Risk Ratio (M-H, Fixed, 95% CI) 2.02 [0.19, 21.92]
Comparison 10. Praziquantel versus metrifonate
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Praziquantel 40 mg/kg single
dose versus metrifonate 10 mg/
kg single dose: parasitological
failure
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 at one month 1 183 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.34, 0.61]
1.2 at two to three months 2 243 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.57, 0.79]
1.3 at six months 1 149 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.79, 1.01]
1.4 at eight months 1 208 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.13, 0.36]
2 Praziquantel 40 mg/kg single
dose versus metrifonate 10 mg/
kg single dose: haemoglobin
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 at baseline 1 208 Mean Difference (IV, Fixed, 95% CI) -0.30 [-0.52, -0.08]
2.2 at eight months 1 208 Mean Difference (IV, Fixed, 95% CI) -0.40 [-0.66, -0.14]
3 Praziquantel 40 mg/kg single
dose versus metrifonate 20 and
30 mg/kg given as split doses:
parasitological failure
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 2 x 10 mg/kg Metrifonate
at one month
1 72 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.80, 1.34]
3.2 2 x 10 mg/kg Metrifonate
at five months
1 67 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.64, 1.05]
3.3 3 x 10 mg/kg Metrifonate
at three months
1 100 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.07, 1.57]
3.4 3 x 10 mg/kg Metrifonate
at six months
1 100 Risk Ratio (M-H, Random, 95% CI) 0.2 [0.02, 1.65]
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4 Praziquantel 40 mg/kg single
dose versus metrifonate 30 mg/
kg given as split dose: adverse
events
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Dizziness 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Abdominal pain 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Joint pain 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 Nausea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 Rash 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.6 Vomiting 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.7 Itching 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.8 Fatigue 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.9 Hair loss 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.10 Change in taste 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.11 Diarrhoea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.12 Convulsion 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Praziquantel 30 mg/kg single
dose versus metrifonate 30
mg/kg given as split dose:
parasitological failure
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 at two months 1 54 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.17, 1.68]
5.2 at four months 1 52 Risk Ratio (M-H, Fixed, 95% CI) 0.24 [0.07, 0.80]
6 Praziquantel 30 mg/kg single
dose versus metrifonate 30 mg/
kg given as split dose: adverse
events
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Nausea 1 60 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 70.83]
6.2 Vomiting 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.2 [0.01, 4.00]
6.3 Abdominal pain 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.12, 0.92]
6.4 Headache 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.87]
6.5 Fever 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.87]
6.6 Loose bowel motions 1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 15.26]
6.7 Dizziness 1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 15.26]
6.8 Itching 1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 15.26]
6.9 Body pain 1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 15.26]
7 Praziquantel 40 mg/kg once a
year versus metrifonate 10 mg/
kg every 4 months
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Parasitological failure at
one year
1 1436 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [1.00, 1.11]
7.2 Haematuria at one year 1 1400 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.85, 1.36]
7.3 Proteinuria at one year 1 1400 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.79, 1.11]
8 Praziquantel 40 mg/kg once
a year versus metrifonate
10 mg/kg every 4 months:
parasitological failure
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 at one year 1 1018 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.61, 1.00]
8.2 at two years 1 1025 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.53, 1.11]
8.3 at three years 1 827 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.42, 0.93]
9 Praziquantel 40 mg/kg versus
praziquantel 10 mg/kg and
metrifonate 10 mg/kg
1 72 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.34, 1.03]
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Comparison 11. Artesunate versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure at eight
weeks
2 251 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.16, 1.71]
2 Haematuria 1 119 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.85, 1.76]
3 Adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Headache 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Vomiting 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Fever 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 Itching 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.5 Cough 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.6 Diarrhoea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.7 Chills 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.8 Nausea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.9 Dizziness 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.10 Abdominal pain 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.11 Constipation 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 12. Praziquantel versus artesunate
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 at day 28 1 46 Risk Ratio (M-H, Random, 95% CI) 0.15 [0.05, 0.46]
1.2 at day 56 2 352 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.23, 1.44]
2 Haematuria 1 178 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.30, 0.62]
3 Adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Abdominal pain 1 208 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Dizziness 1 208 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Headache 1 208 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.43, 2.30]
3.4 Vomiting 1 208 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.26, 3.89]
3.5 Fever 1 208 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.41, 3.35]
3.6 Itching 1 208 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.26, 3.89]
3.7 Cough 1 208 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.14, 6.97]
3.8 Diarrhoea 1 208 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.9 Chills 1 208 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.26, 8.79]
3.10 Nausea 1 208 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.14, 6.97]
3.11 Constipation 1 208 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.12, 72.80]
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Comparison 13. Praziquantel and artesunate versus praziquantel
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure at eight
weeks
2 265 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.38, 0.99]
2 Haematuria at eight weeks 1 177 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.40, 1.18]
3 Adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Abdominal pain 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Dizziness 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Headache 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 Vomiting 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.5 Fever 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.6 Itching 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.7 Cough 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.8 Diarrhoea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.9 Chills 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.10 Nausea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.11 Constipation 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 14. Mefloquine versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure at six
weeks
1 44 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.40, 0.83]
Comparison 15. Praziquantel versus mefloquine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure at one
month
1 45 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.05, 0.43]
85Drugs for treating urinary schistosomiasis (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Comparison 16. Praziquantel versus artesunate and mefloquine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure at one
month
1 44 Risk Ratio (M-H, Fixed, 95% CI) 0.23 [0.07, 0.74]
Comparison 17. Praziquantel versus praziquantel and albendazole
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure 1 193 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.62, 1.30]
Comparison 18. Praziquantel versus praziquantel and artesunate
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitological failure at eight
weeks
2 265 Risk Ratio (M-H, Fixed, 95% CI) 1.62 [1.01, 2.60]
2 Haematuria at eight weeks 1 177 Risk Ratio (M-H, Fixed, 95% CI) 1.45 [0.85, 2.50]
3 Adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Abdominal pain 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Dizziness 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Headache 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 Vomiting 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.5 Fever 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.6 Itching 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.7 Cough 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.8 Diarrhoea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.9 Chills 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.10 Nausea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.11 Constipation 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
86Drugs for treating urinary schistosomiasis (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
A D D I T I O N A L T A B L E S
Table 1. Population based treatment according to prevalence among schoolchildren (WHO)
Category
Prevalence among school-aged
children
Action to be taken Comment
High-risk community 50% by parasitological methods
(intestinal or urinary schistoso-
miasis;
or
30% by questionnaire for visible
haematuria
(urinary schistosomiasis)
Treat all school-age children (en-
rolled and not enrolled) once a
year
Also treat adults considered to be
at risk (from special groups to
entire communities living in en-
demic areas)
Moderate-risk community > 10 to < 50% by parasitological
methods (intestinal and urinary
schistosomiasis); or
30% by questionnaire for visible
haematuria (urinary schistosomi-
asis)
Treat all school-age children (en-
rolled or not enrolled) once every
two years
Also treat adults considered to be
at risk (special groups only)
Low-risk community < 10% by parasitological meth-
ods (intestinal and urinary schis-
tosomiasis)
Treat all school-age children
(enrolled and not enrolled) twice
during their primary schooling
age
(for example, once on of sus-
pected cases
entry and once on exit)
Praziquantel should be available
in dispensaries and clinics for
treatment of suspected cases
Table 2. Definion of cure, reporting and calculation of egg counts
Study ID Definition cure Reporting of egg
counts/10 mL urine
Methods to calculate
egg counts
Comment
Abden Abdi 1989 SOM Patients without schisto-
some eggs in their urine
after treatment
Mean (SD), % ER Not reported No hatching test em-
ployed, cured might be
underestimated because
of dead eggs
Al Aska 1990 SAU Clinical improvement
Disappearance of ova
from the urine on three
successive examinations
Mean, range Not reported -
Basra 2012 GAB Three consecutive urine
samples without pres-
ence of eggs
Median, interquartile
range
Not reported -
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Table 2. Definion of cure, reporting and calculation of egg counts (Continued)
Befidi Mengue 1992
CMR
Cure not reported GMEC Not reported Hb and weight as out-
comes
Borrmann 2001 GAB Two negative egg counts
on two consecutive days
GMEC Arithmetric mean of two
egg counts per partici-
pant
before and after treat-
ment including 0 egg
counts (cured patients)
. Geometric means of
these arithmetic means
We received the data file
from the study author
Day to day variation in
egg counts explains 10%
cure rate with placebo
Davis 1981 ZMB Defined as three neg-
ative urine defined as
the absence of hatched
miracidia, although re-
cently dead or black eggs
might be present
Geometric mean
miracidial count
At follow-up: If the
first urine specimen con-
tained
hatched miracidia, then
random 10 mL samples
were taken from fur-
ther bladder collections,
the miracidial count was
recorded, and the ge-
ometric mean of the
counts was compared di-
rectly with the geomet-
ric mean of the pretreat-
ment counts
Quantitaive hatching
test.
if the first sedimented
urine specimen was neg-
ative, then two further
urine specimens taken
on consecutive days were
sedimented and exam-
ined
de Jonge 1990 SDN No definition of cure
given, presumably ab-
sence of urinary egg ex-
cretion
Minimum and max-
imum value, median,
90%value
Not reported Excretion of eggs follow-
ing treatment
Inyang Etoh 2009 NGA No definition of cure
given, cure rates and egg
reduction rates as end
points
Mean ± SD “Treatment-related
changes
in egg counts were inves-
tigated using paired Stu-
dent’s t
test.”
-
Jewsbury 1976 ZWE No definition of cure
given
“median urine egg
count”
Not reported -
Kardaman 1985 SDN No definition of cure
given, “negative”
GMEC Not reported “It would appear that the
cure rate determined in
any trial is dependent
on the pretreatment egg
count and on the ...urine
examination techniques
used.”
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Table 2. Definion of cure, reporting and calculation of egg counts (Continued)
Keiser 2010 CIV Absence of urinary egg
excretion
Cure rate (CR, defined
as the percentage of chil-
dren excret-
ing no S. haematobium
eggs 26 days after treat-
ment among children
with confirmed parasites
at baseline)
GMEC S. haema-
tobium egg counts be-
fore and after treatment
were averaged for every
child (arithmetic mean)
and the GM egg count
for each treatment group
was calculated. Because
egg counts are over dis-
persed, they were loga-
rithmically transformed
log [count+1], and the
GM was expressed as
the antilogarithm of the
mean
Egg reduction rate
(ERR) defined as reduc-
tion of geometric mean
(GM) egg count among
S. haematobium positive
children after treatment,
compared with the re-
spective GM pretreat-
ment
The ERR was calculated
as (1 - [GM egg count
after treatment/GM egg
counts at enrolment] x
100
(ERR; defined as reduc-
tion of geometric mean
egg count
among S. haematobium-
positive children after
treatment, compared
with the respective ge-
ometric mean pretreat-
ment)
King 1989 KEN No definition of cure
given
AMEC
GMEC
Not reported Infection was identified
and quantified byNucle-
opore filtration
King 1990 KEN No definition of cure
given
AMEC
GMEC
Not reported Infection was identified
and quantified byNucle-
opore filtration
King 2002 KEN Cure defined as egg-neg-
ative
GMEC Not reported -
McMahon 1979 TZA Probable cure rate: excre-
tion of no or only non vi-
able eggs in the urine
GMEC, 95%confidence
limit of the mean
Not reported -
McMahon 1983 TZA People were considered
cured when no eggs or
non-viable eggs were ex-
creted in the urine
Screening: GMEC of
miracidia/10 mL urine
reduction in egg excre-
tion
“In non cured cases the
reduction of egg excre-
tion was calculated.”
-
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Table 2. Definion of cure, reporting and calculation of egg counts (Continued)
Mott 1985 GHA Absence of S. haemato-
bium eggs in two random
5 mL samples of urine
from the same specimen
GMEC 5mL urine sam-
ples
reduction in GMEC
Not reported -
Olds 1999 KEN No definition given GMEC “Egg counts are geomet-
ric means in subjects
who remained
infected. Reduction in
egg no. after treatment in
infected childrenwas sig-
nificant in all infections
at 45 days.”
-
Omer 1981 SDN 100% reduction of egg
excretion (absence of egg
excretion in the urine)
or 98% egg reduc-
tion and neg miracidial
hatching test
GMEC Not reported Only
children with GMEC >
60/10 mL (in three egg
counts) included
Oyediran 1981 NGA No definition of cure
given
GMEC mean ± SD Not reported Only
children with GMEC >
60/10 mL (in three egg
counts) included
Pugh 1983 MWI No definition of cure
given
AMEC
% egg count reduction
Percentage reduction in
egg output was deter-
mined by comparing the
arithmetic and geomet-
ric means of pooled egg
counts before and after
treatment. The geomet-
ricmeanwas obtained by
recording the logarithm
of egg counts and using
the n +1 transformation
for a series of counts after
treatment that included
zeros
We did not use a hatch-
ing test to determine the
viability of excreted ova
since percentage reduc-
tion in egg output rather
than parasitological cure
was ourmain criterion of
efficacy
Rey 1983 NER No definition of cure
given
AMEC
“nombre moyenne”
average number
Not reported If possible, a hatching
test was that at the last
control (6 months)
Rey 1984 NER No definition of cure
given, “negativation”
AMEC
moyenne des nombres
d’oeufs/10 mL urine
Number average
Not reported -
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Table 2. Definion of cure, reporting and calculation of egg counts (Continued)
Sacko 2009 MLI The
cure rate was calculated
as the proportion of in-
fected individuals who
became parasitologically
negative (0 egg/10 mL
urine based on three
urine samples) at three
months post treatment
GMEC Individual egg counts
were
calculated as the mean
number of eggs per 10
mL of urine in the three
urine samples. To com-
pare the effect of the
treatment on the inten-
sity of the infection at 3,
6 and 18 months geo-
metric mean egg/10 mL
for all urine samples ex-
amined for S. haemato-
bium eggs were calcu-
lated as log10(x+1) to al-
low egg count of
0 to be included in the
analysis.
-
Stephenson 1985 KEN no definition of cure
given
AMEC Not reported -
Stephenson 1989 KEN - AMEC
GMEC
Not reported -
Taylor 1988 ZWE Cure defined as negative
egg counts
“infections as were cured
by a negative GMEC at
1,3 and 6 months”
GMEC Not reported “in cases were only one
egg was found in three
(urine) examinations the
egg count was always
taken as positive.”
Tchuente 2004 CMR The parasitologic cure
rates were calculated as
the proportion
of children
excreting eggs at the first
survey before treatment
andwhowere not excret-
ing eggs in their urine af-
ter treatment
GMEC Geometric mean (GM)
values of all
individuals were used to
assess average egg counts
of each group. The GM
was calculated as the an-
tilogarithm of the
mean of all log trans-
formed egg counts + 1.
The intensity reduction
rate was calculated as [1
− (GM egg counts per
10
mL of urine after treat-
ment/GM egg counts
per 10 mL before treat-
ment)] × 100
The parasitological cure
rates were calculated as
the proportion of chil-
dren excreting eggs at the
first survey before treat-
ment and who were not
excreting eggs in their
urine after treatment
91Drugs for treating urinary schistosomiasis (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Table 2. Definion of cure, reporting and calculation of egg counts (Continued)
van den Biggelaar 02
GAB
Negative for both eggs
and circulating antigen
failure: pos. for eggs or
circulating antigen
GMEC interquartile
range
Not reported -
Wilkins 1987 GMB No definition of cure
given
GMEC When appro-
priate a log10 transfor-
mation was used in sta-
tistical analysis to make
their skeweddistribution
approximate to normal.
This was reversed for the
presentation of results to
give a geometric mean
which included zero val-
ues
-
Table 3. Praziquantel 40 mg/kg single dose versus placebo: % egg reduction at one and two months
Study ID Sub-
group
Time-
point
Measure Praziquantel 40 mg/kg single
dose
Placebo P
value dif-
ference
between
groups
Egg count/10 mL
(Range/95% CI)
N
% egg re-
duction
Egg count/10 mL
(Range/95% CI)
N
% egg re-
duction
Baseline Follow-
up
Baseline Follow-
up
de Jonge
1990
SDN
- 1 month Median 66
N = 48
1
N = 40
98.5 124
N = 21
58
N = 18
53.2 P = 0.29
not sig-
nificant
McMa-
hon
1979
TZA
- 1 month
Miracidial
count
(95% CI)
288.
4 (33.2 to
2508.9)
N = 32
1.1 (0 to
8.3) N =
30
99.6 324.9
(22.1 to
4783.3)
N = 37
187.5
(6.3 to
5601.3)
N = 29
42.3 Not
reported
Pugh
1983
MWI
- 1 month GMEC
AMEC
385.5
780.9
N = 97
1.8/
1.8
99.5
99.7
136.8
188.8
N = 52
119.9
437.2
12.35
(GMEC)
- 131.5
(AMEC)
(increase)
Not
reported
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Table 3. Praziquantel 40 mg/kg single dose versus placebo: % egg reduction at one and two months (Continued)
Taylor
1988
ZWE
light in-
fections
< 50/10
mL
1 month GMEC
N = (both
light and
heavy)
15.1
N = 77
(both
groups)
0.4 99.7 15.7
N = 90
(both
groups)
37.5 -138
(increase)
Not
reported
heavy in-
fections
< 100/10
mL
1 month GMEC
N = (both
light and
heavy)
204.7
N = 77
(both
groups)
4.0 98.1 191.9
N = 90
(both
groups)
147.0 23.39 Not
reported
Olds
1999
KEN
- 45 days GMEC Not
reported
N = 95
1.4 - N = 94 29.8 - Not
reported
Bor-
rmann
2001
GAB
- 8 weeks GMEC
(range)
38.51
(1 to
3313)
N = 90
1.11
N = 89
97.11 21.57
(1 to 778)
N = 30
11.41
N = 30
47.1 Signifi-
cant
Inyang
Etoh
2009
NGA2
without
placebo
8 weeks - 42.0 ±1.7
N = 52
9.8 ± 0.5
N = 42
76.7 34.1±0.8
N = 52
72.0±2.3
N = 44
- 111.5
(increase)
P < 0.001
2
1P for therapeutic efficacy (not defined) Praziquantel versus placebo
2 Treatment group: Praziquantel 40mg/kgwithout placebo. Inyang Etoh 2009 NGAalso reports a second treatment group (Praziquantel
40 mg/kg with placebo), data not shown.
Table 4. Praziquantel 40 mg/kg single dose versus placebo: % egg reduction at later time points
Study ID Sub-
group
Time
point
Measure Praziquantel 40 mg/kg single
dose
Placebo P
value for
differ-
ence be-
tween
groups
Egg count /10 mL
urine
% egg re-
duction
Egg count/10 mL
urine
% egg re-
duction
Baseline Follow-
up
Baseline Follow-
up
McMa-
hon
1979
TZA
- 3 months
miracidial
count
(95% CI)
288.
4 (33.2 to
2508.9)
N = 32
1.1 (0 to
16.3)
99.6 324.9
(22.1 to
4783.3)
N = 37
149.4
(6.3 to
3556.6)
54 Not
reported
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Table 4. Praziquantel 40 mg/kg single dose versus placebo: % egg reduction at later time points (Continued)
Pugh
1983
MWI
- 3 months GMEC
AMEC
385.5
780.9
N = 97
1.9
1.9
99.5
(GMEC)
99.75
(AMEC)
136.8
188.8
N = 52
85.9
270.3
37.2
(GMEC)
43.16
(AMEC)
Not
reported
Taylor
1988
ZWE
light in-
fections
< 50/10
mL
3 months GMEC 15.1
N = 77
(for both
groups)
0.4 97.35 15.7
N = 90
19.8 -26.11
(increase)
Not
reported
heavy in-
fections
< 100/10
mL
GMEC 204.7
N = 77
(for both
groups)
2.0 99.02 191.9
N = 90
94.7 50.65 Not
reported
de Jonge
1990
SDN
- 5 months median 66
N = 48
0 100 124
N = 21
95 23.38 P = 0.27
not sig-
nificant
McMa-
hon
1979
TZA
- 6 months
miracidial
count
(95% CI)
288.
4 (33.2 to
2508.9)
N = 32
1.1
(0-20.3)
99.6 324.9
(22.1 to
4783.3)
N = 37
188.
6 (13.9 to
2563.5)
41.95 Not
reported
Pugh
1983
MWI
- 6 months GMEC
AMEC
385.5
780.9
N = 97
2.4
20.1
99.3
(GMEC)
97.4
(AMEC)
136.8
188.8
N = 52
69.7
261.8
49.0
GMEC
-38.7
(increase)
AMEC
Not
reported
Befidi
Mengue
1992
CMR
- 6 months GMEC 41/10
mL
N = 238
2/10 mL 95.1 39/10
mL
N = 198
14/10
mL
64.1
Taylor
1988
ZWE
light in-
fections
< 50/10
mL
6 months GMEC 15.1
N = 77
(for both
groups)
0.2 98.67 15.7
N = 90
11.7 25.5 Not
reported
heavy in-
fections
< 100/10
mL
204.7
N = 77
(for both
groups)
0.6 99.7 191.9
N = 90
75.5 60 Not
reported
Stephen-
son
1989
KEN
- 8 months GMEC
AMEC
57/
112
N = 105
0.2/
1
99.64
(GMEC)
99.1
38/
85
N = 104
36/
102
5.26
(GMEC)
-20
Not
reported1
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Table 4. Praziquantel 40 mg/kg single dose versus placebo: % egg reduction at later time points (Continued)
(AMEC) (increase)
(AMEC)
1Praziquantel 40 mg/kg single dose: significant egg reduction in praziquantel group (before, after treatment) P < 0.0002. no significant
reduction in the placebo group (before, after treatment).
Table 5. Praziquantel 40 mg/kg single dose versus 30 mg/kg single dose: % egg reduction
Study ID Sub-
group
Time
point
Measure Praziquantel 40 mg/kg (SD) Praziquantel 30 mg/kg (SD) P
value dif-
ference
between
groups
Egg count/10 mL
urine
% reduc-
tion
Egg count/10 mL
urine
% reduc-
tion
Baseline Follow-
up
Baseline Follow-
up
McMa-
hon
1979
TZA
- 1 month GMEC
(95 Con-
fidence
limits of
mean)
N
288.
4 (33.2 to
2508.9)
N = 33
1.1 (0-8.
3)
N = 30
99.61 308.
5 (31.2 to
3034.7)
N = 32
1.2 (0 to
15.4)
N = 31
99.6 Not sig-
nificant
P
value not
reported
Rey 1983
NER1
- 1 month AMEC
N
7.5 ± 1.7
N = 57
0.24
N = 54
96.8 7.5 ± 1.7
N = 46
0.74
N = 39
90.13 Not sig-
nificant
Taylor
1988
ZWE2
heavy in-
fection
< 100/10
mL
1 month GMEC
N
204.7
N = 77
for both
groups
4.0 98.04 185.4
N = 72
for both
groups
3.1 98.32 Not
reported
light in-
fection
> 50/10
mL
1 month GMEC 15.1 0.4 97.35 15.9 0.6 96.23
Oyediran
1981
NGA3
- 1 month GMEC
mean ±
SE,
N =
Stratum 1
87.4±23.
46
N = 15
Stratum 2
339.4 ±
32.61
N = 5
Stratum 3
N = 21 97.69±0.
98
Stratum
1:
111.67 ±
47.14
N = 15
Stratum
2:
306.83 ±
54.29
N = 19 85.65 ±
13.08
Not sig-
nificant
Not
reported
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Table 5. Praziquantel 40 mg/kg single dose versus 30 mg/kg single dose: % egg reduction (Continued)
518.00 ±
0.71
N = 2
N = 22
(N = 6)
Stratum
3:
1507.00
± 1400.
07
N = 2
N = 23
King
1989
KEN
2-3
months
AMEC (±
SD)
GMEC
N =
377
255
N = 64
31 (± 21)
2
N = 54
91.7
(AMEC)
99.2
(GMEC)
327
204
N = 69
22 ± 17
2
N = 60
93.27
(AMEC)
99
(GMEC)
Not sig-
nificant
Not
reported
McMa-
hon
1979
TZA
3 months GMEC
(95 Con-
fidence
limits of
mean)
N
288.
4 (33.2 to
2508.9)
N = 33
1.1 (0-16.
3)
N = 29
99.61 308.
5 (31.2 to
3034.7)
N = 31
0.9 (0 to
13.4)
N = 31
97.08 Not sig-
nificant
Not
reported
Rey 1983
NER
3 months AMEC
N =
7.5 ± 1.7
N = 57
0.42
N = 52
94.4 7.5 ± 1.7
N = 46
1.21
N = 42
83.86 Not
reported
Taylor
1988
ZWE3
heavy in-
fections <
100/10
mL
3 months GMEC
N =
204.7
N = 77
for both
groups
2.0 99.02 185.4
N = 72
for both
groups
1.1 99.4 Not
reported
light in-
fections >
50/10
mL
3 months GMEC 15.1 0.4 97.35 15.9 0.4 97.48
Oyediran
1981
NGA3
- 3 months GMEC
mean ±
SE,
N =
Stratum 1
87.4±23.
46
N = 15
Stratum 2
339.4 ±
32.61
N = 5
Stratum 3
518.00 ±
0.71
N = 2
N = 22
97.55±0.
85 (N =
18)
Stratum 1
111.67 ±
47.14
N = 15
Stratum 2
306.83 ±
54.29
N = 6
Stratum 3
1507.00
± 1400.
07
N = 2
N = 23
99.01±0.
47 (N =
19)
Not sig-
nificant
Not
reported
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Table 5. Praziquantel 40 mg/kg single dose versus 30 mg/kg single dose: % egg reduction (Continued)
McMa-
hon
1979
TZA
- 6 months GMEC
(95 Con-
fidence
limits of
mean)
288.
4 (33.2 to
2508.9)
N = 33
1.1 (0 to
20.3)
N = 28
99.6 308.
5 (31.2 to
3034.7)
N = 32
1.4 (0 to
39.5)
N = 28
99.46 Not sig-
nificant
Not
reported
Rey 1983
NER
- 6 months AMEC 7.5 ± 1.7
N = 57
4
N = 34
46.6 7.5 ± 1.7
N = 462
0.18
N = 28
97.6 Not
reported
Taylor
1988
ZWE3
heavy in-
fections <
100/10
mL
6 months GMEC
N =
204.7 (N
= 77)
0.6 99.7 185.4 (N
= 72)
0.7 99.62 Not sig-
nificant
Not
reported
light in-
fections >
50/10
mL
6 months GMEC
N =
15.1 (N =
77)
0.2 98.67 15.9 (N =
72)
0.1 99.37
Oyediran
1981
NGA4
- 6 months GMEC
mean ±
SE,
(N =)
Stratum 1
87.4±23.
46
(N = 15)
Stratum 2
339.4 ±
32.61
(N = 5)
Stratum 3
518.00 ±
0.71
(N = 2)
(N = 22)
(N = 15) 93.09±0.
12
Stratum 1
111.67 ±
47.14
(N = 15)
Stratum 2
306.83 ±
54.29
(N = 6)
Stratum 3
1507.00
± 1400.
07
(N = 2)
(N = 23)
(N = 17) 98.72±0.
28
Not sig-
nificant
Not
reported
- 9 months (N = 6) 92.4 ± 5.
92
(N = 8) 96.49±1.
59
- 12
months
(N = 3) 99.3 ± 0.
26
(N = 4) 99.28±0.
46
1Baseline data not reported separately per group.
2A reduction as low as 46% after praziquantel 40 mg/kg was not observed by any other study that reported this outcome. At six months,
five other studies reported % egg reduction above 90% (see Table 4 and Table 5)
3Heavy and light infections together; N = 77 for Praziquantel 40 mg/kg and N = 72 for Praziquantel 30 mg/kg.
4 GMEC/10 mL urine, stratum 1: 60 to 250, stratum 2: 251 to 500, stratum 3 > 500.
Table 6. Praziquantel 40 mg/kg multiple doses versus single dose: % egg reduction
Study ID Time
point
Measure Praziquantel 40 mg/kg
single dose
% egg re-
duction
Praziquantel 40 mg/kg
multiple doses
% egg re-
duction
Com-
ments
Egg count/10 mL Egg count/10 mL
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Table 6. Praziquantel 40 mg/kg multiple doses versus single dose: % egg reduction (Continued)
Baseline Follow-up Baseline Follow-up
van den
Biggelaar
02 GAB1
2 years GMEC
(IQR)
47
N = 45
9 (2-45) 80.85 47
N = 45
2 (1-3) 95.74 Significant
P = 0.002
1Baseline egg counts not reported separately per treatment group; no difference at baseline stated. Praziquantel 40 mg/kg given every
3 months over 2 years. Location: Gabon, endemic area.
Table 7. Metrifonate 20 mg/kg given as divided dose versus placebo: % egg reduction
Study ID Time
point
Measure Metrifonate 21.5 mg, 20 mg/kg
given as divided dose
Placebo or no treatment P value
difference
between
groups
Egg count/10 mL urine % egg re-
duction
Egg count/10 mL urine % egg re-
duction
Baseline Follow-up Baseline Follow-up
de Jonge
1990 SDN
1
1 month median
N =
(re-
ports min,
max, 90th
percentile
and
median
of egg
counts/10
mL)
95
N = 38
1
N = 32
98.94 124
N = 21
58
N = 18
53.22 Not signif-
icant
P = 0.29
Jewsbury
1976
ZWE2
11 weeks median
N =
101
N = 32
0 100 26
N = 38
60 -130.77
(increase)
Not
reported
11 weeks median
N =
40
N = 23
0 100
de Jonge
1990 SDN
1
5 months median
N =
(re-
ports min,
max, 90th
percentile
and
median
124
N = 38
1
N = 32
99.19 124
N = 21
95
N = 19
23.38 Not signif-
icant
P = 0.27
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Table 7. Metrifonate 20 mg/kg given as divided dose versus placebo: % egg reduction (Continued)
of egg
counts/10
mL)
Stephen-
son
1985 KEN
3
6 months AMEC
N =
109
N = 202
7 94 110
N = 198
124 -12.7
(increase)
Not
reported
1Metrifonate 2 x 10 mg/kg, dose interval two weeks. Placebo: multivitamins.
2Reports two groups with metrifonate 7.5 mg x 3, dose interval two weeks. Control group: nil.
3 Metrifonate 3 x 7.5 mg/kg, dose interval one to two weeks.
Table 8. Artesunate versus placebo: % egg reduction
Study ID Time
point
Measure Artesunate 4 mg/kg/d for 3 days Placebo P value
difference
between
groups
Egg count/10 mL urine % egg
reduction
Egg count/10 mL % egg
reduction
Baseline Follow-up Baseline Follow-up
Borrmann
2001 GAB
8 weeks GMEC
(range)
95% CI N
=
35.22 (1-
4360)
N = 90
10.8
N = 89
69.34 21.56
(1-778)
N = 30
11.41
N = 30
47.1 Not signif-
icant
Inyang
Etoh 2009
NGA1
8 weeks Mean
ova count
± SD
N =
39.8 ± 1.1
N = 52
19.1 ± 1.0
N = 44
52.1 34.1 ± 0.8
N = 52
72.0 ± 2.3
N = 44
111.5
(increase)
P for “ther-
apeutic ef-
ficacy” < 0.
001
1Treatment group: Praziquantel 40mg/kg without placebo. Inyang Etoh 2009 NGA also reports a second treatment group (Praziquantel
40 mg/kg with placebo), data not shown.
Table 9. Praziquantel and Artesunate versus Praziquantel: % egg reduction
Study ID Time
point
Measure Praziquantel 40 mg/kg single dose
and artesunate 4 mg/kg/d for 3 days
Praziquantel 40 mg/kg single dose P value
difference
between
groups
Egg count/10 mL % egg re-
duction
Egg count/10 mL % egg re-
duction
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Table 9. Praziquantel and Artesunate versus Praziquantel: % egg reduction (Continued)
Baseline Follow-up Baseline Follow-up
Borrmann
2001 GAB
8 weeks GMEC
(range),
(95% CI)
N =
31.5
(1 to 3225)
N = 90
0.36
N = 88
98.8 38.51
(1 to 3313)
N = 90
1.11 (0.7
to 1.7)
N = 89
97.11 Not signif-
icant
Inyang
Etoh 2009
NGA1
8 weeks mean ± SD
N =
62.2 ± 2.1
N = 52
4.0 (± 15.
2) N = 44
93.6 39.8 (± 1.
1)
N = 52
19.1 (± 1.
0)
N = 44
52.1 Not
reported
1Treatment group: Praziquantel 40mg/kg without placebo. Inyang Etoh 2009 NGA also reports a second treatment group (Praziquantel
40 mg/kg with placebo), data not shown.
WH A T ’ S N E W
Last assessed as up-to-date: 23 May 2014.
Date Event Description
7 July 2014 New search has been performed The reviewhas beenupdated and revisedwith a new author
team
7 July 2014 New citation required but conclusions have not changed A new author teamwas put in place for this review update.
C O N T R I B U T I O N S O F A U T H O R S
VK developed the protocol with input from PG and DS. VK and FZ assessed eligibility and extracted the data. We resolved any
disagreements through discussion with DS and PG. VK entered the data and drafted the manuscript with input from DS, PG and PO.
DS, PG and PO assisted in interpretation of the results and revisions of the text.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
While inclusion criteria of the first protocol included all RCTs which studied antischistosomal drugs, we decided to change the protocol.
We excluded trials which evaluated obsolete drugs as ambilhar, oltipraz and niridazole. We also excluded studies which compared a
combination of praziquantel and albendazole to placebo only, as this comparison is not of interest for this review. We included trials
evaluating metronidazole.
We did not contact researchers or organizations looking for unpublished studies, as stated in the protocol. We did not report parasito-
logical outcomes at three months as primary outcomes.
The older version of this review concluded that both metrifonate and praziquantel were effective in treating urinary schistosomiasis,
even if metrifonate had operational disadvantages. As implications for further research, evaluation of different metrifonate doses and
regimens and of evaluation of artemisinin drugs and of combination therapy is recommended.
While we agree with these conclusions, the data on egg reduction allow some further recommendations. We have newly included three
trials evaluating artemisinin drugs, and one recent trial using mefloquine, and present this new evidence here.
Additional analysis carried out in this edition of the review, which was not in the previous edition (Danso-Appiah 2008), is the
presentation of egg reduction rates in summary tables.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anthelmintics [∗therapeutic use]; Artemisinins [therapeutic use]; Mefloquine [therapeutic use]; Praziquantel [therapeutic use]; Ran-
domized Controlled Trials as Topic; Schistosomiasis haematobia [∗drug therapy]; Trichlorfon [therapeutic use]
MeSH check words
Adult; Child; Humans
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